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ABSTRACT 
Opioids such as morphine have many beneficial properties as analgesics, however, 
opioids may induce multiple adverse gastrointestinal symptoms. It has been recently 
demonstrated that morphine treatment results in significant disruption in gut barrier 
function leading to increased translocation of gut commensal bacteria. However, it is 
unclear how opioids modulate gut homeostasis.  
A mouse model was used to investigate the effects of morphine treatment on gut 
microbiome and metabolome. When phylogenetic profiles of gut microbes were 
characterized, the results revealed a significant shift in the colonic microbiome following 
morphine treatment when compared to placebo. At the species level, Enterococcus faecalis 
was associated with morphine-modulated gut microbiome alteration. Morphine treatment 
also resulted in dramatic changes in the fecal metabolomic profile. Through LC-MS based 
metabolomics profiling analysis, fatty acids and bile acids metabolism and in particular, 
deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) was identified to be greatly 
affected by morphine treatment, implicating that changes in the microbiome community 
has functional consequences. In a longitudinal study, naltrexone, an opioid receptor 
antagonist, reversed the effect of morphine on bile acid metabolism, indicating morphine 
induced changes are opioid receptor dependent. Cross-correlation between gut microbiome 
and metabolome indicated association between bacterial communities and functional 
metabolites. Furthermore, morphine induced dysbiosis disrupts morphine metabolism and 
its enterohepatic recirculation. This study shed light on the effects of morphine on the 
microbiome-metabolome-host axis, and its role in gut homeostasis.  
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In a mouse model of Citrobacter rodentium infection, morphine treatment resulted 
in 1) the promotion of C. rodentium systemic dissemination, 2) increase in virulence factors 
expression with C. rodentium colonization in intestinal contents, 3) altered gut microbiome, 
4) damaged integrity of gut epithelial barrier function, 5) inhibition of C. rodentium-
induced increase of goblet cells, and 6) dysregulated IL-17A immune response. This is the 
first study to demonstrate that morphine promotes pathogen dissemination in the context 
of intestinal C. rodentium infection, indicating morphine modulates virulence factor-
mediated adhesion of pathogenic bacteria and induces disruption of mucosal host defense 
during C. rodentium intestinal infection in mice.  
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CHAPTER 1  
BACKGROUND-LITURATURE REVIEW 
1. GUT HOMEOSTSIS 
A. Concepts of gut homeostasis and dysbiosis 
a. Gut homeostasis and health 
The gut is a complex and dynamic network where interaction between 
host and gut microbiota establishes a balanced, symbiotic, and mutual 
beneficial relationship(Kau et al. 2011). Gut homeostasis refers to the state of 
resilience and resistance to external and endogenous disturbance(Lozupone et 
al. 2012). Gut homeostasis is established and maintained by commensal 
microbiota, functional barrier and tolerant immune response(E. M. Brown, 
Sadarangani, and Finlay 2013). Gut microbiota is the sum of all 
microorganisms within gastrointestinal tract, including bacteria, bacteria, 
archaea, eukaryotes and viruses(Gordon 2012). It is estimated that almost 
1013-1014 bacteria inhabit the gastrointestinal tract, which is two orders of 
magnitude more than host cells(Relman 2012). Unborn fetus lives in a 
basically sterile environment. During birth and thereafter, infants are exposed 
to the external environment whereby the gut microbial community is 
initialized, established and develop gradually(Dominguez-Bello et al. 2010). 
The gut microbiota becomes stable and adult-like at approximately 3-5 years 
old(Rodrı et al. 2015). It has been demonstrated that microbiota play 
important roles in modulating host neural and immune development, 
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morphogenesis, as well as resistance to diseases(Sommer and Bäckhed 2013). 
The mechanisms by which the gut microbiota maintains a healthy state and 
how microbial dysbiosis increases susceptibility to diseases is largely 
unknown.  
b. Microbial dysbiosis and diseases  
Microbial dysbiosis refers to a change of the structural and/or 
functional configuration of gut microbiota, which causes disruption of gut 
homeostasis and is associated with a variety of diseases, such as obesity, 
diabetes, autoimmune, allergic, inflammatory and infectious diseases,(Gordon 
2012; Sommer and Bäckhed 2013). Recent rapid progress in metagenomics 
provides powerful tools to determine perturbation of the human microbiome 
as a contributor to diseases(Gordon 2012). Changes in composition or density 
of the microbiota may leads to higher susceptibility to a variety of pathogens 
and abnormal mucosal immune responses(Wells et al. 2011; Stecher and 
Hardt 2008). For example, antibiotic-induced shifts in the mouse gut 
microbiome and metabolome increase susceptibility to Clostridium difficile 
infection(Theriot et al. 2014). Meanwhile, dysregulation of host immune 
defense can also change gut microbiota during host-microbe interactions(E. 
M. Brown, Sadarangani, and Finlay 2013). For instance, Salmonella enterica 
serotype Typhimurium (S. typhimurium) causes acute gut inflammation, which 
can shift the gut microbiota in favor of the pathogen growth(Stecher et al. 
2007). S. typhinurium induced intestinal inflammation can promote the 
production of respiratory electron acceptor, tetrathionate, which provides a 
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growth advantage for S. typhinurium(Winter et al. 2010). Although it is still 
unclear about causal-consequence relationship, a variety of diseases is 
associated with a vicious circle of microbial dysbiosis, gut barrier dysfunction, 
and dysregulated immune response. HIV-1 infection induced alteration of 
intestinal mucosal microbiome is associated with mucosal and systemic 
immune activation and endotoxemia(Dillon et al. 2014). Dysregulated 
immune response in inflammatory bowel disease has been shown to be 
associated with dysfunction of the intestinal microbiome(Morgan et al. 2012). 
Mechanistic links between gut microbial community dynamics, microbial 
functions and metabolic health are basically unknown and attract attention 
from both clinical therapeutics and basic research(Ha, Lam, and Holmes 
2014).  
The association between the signature of microbial dysbiosis and 
diseases demonstrates potential diagnostic application in monitoring onset and 
progress of the disease. Intestinal Prevotella copri can play a potentially 
diagnostic role based on its strong correlation with enhanced susceptibility to 
arthritis in a gut microbiome study of new-onset untreated rheumatoid arthritis 
(NORA) patients(Scher et al. 2013). After characterization of gut microbiome 
in patients with liver cirrhosis with healthy human subjects, 15 biomarkers 
have been identified as signature of  alterations of the human gut microbiome 
in liver cirrhosis(Qin et al. 2014). Biomarkers specific to liver cirrhosis as a 
powerful tool in differential diagnosis have been confirmed by a comparison 
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with those for type 2 diabetes and inflammatory bowel diseases(Qin et al. 
2014).  
An altered microbiome is not only a marker of disease, but also 
actively contribute to pathogenesis of disease(Chassaing et al. 2012). The 
causal relationship is established when healthy host display the disease 
phenotype after the microbiome transplantation from diseased donors and 
controls into healthy germ-free hosts(Turnbaugh et al. 2006; Faith et al. 2014). 
In order to determine direct causal relationship between microbiome and 
disease, the approach of microbiome transplantation has been conducted in 
studying multiple diseases, such as colitis, type I diabetes, metabolic 
diseases(Elinav et al. 2011; Koren et al. 2012; Wen et al. 2008; Garrett 2013).  
Another important unanswered question is the relationship between the 
microbiome and therapeutic treatment. Probiotics and prebiotics have a long 
history as therapeutic tool in treating diarrhea, vaginal yeast infections, 
urinary tract infections, irritable bowel syndrome, and preventing or reducing 
the severity of colds and flu(Leyer et al. 2009; Vouloumanou et al. 2009; 
Borges, Silva, and Teixeira 2014; Ciorba 2012). Recently, fecal microbial 
transplantation has been conducted effectively in treating recurrent 
Clostridium difficile infection(Weingarden et al. 2014). The administration of 
prebiotics (oligofructose) to genetically obese mice can decrease fat to muscle 
mass ratio, improve glucose and lipid metabolism, reduce plasma LPS, 
improve gut barrier function and increase enteroendocrine L-cell number in 
obese mice(Everard et al. 2011). Administration of oligofructose can induce 
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change of gut microbiota and increase the abundance of Akkermansia 
muciniphila by 100 fold in obese mice(Everard et al. 2011). Further study 
from the same research group shows that the abundance of A. muciniphila 
decreased in obese and type 2 diabetic mice, while administration of A. 
muciniphila reduces body weight, improves metabolic disorders and 
counteracts mucosal barrier dysfunction in obese mice(Everard et al. 2013). 
Remedies for gut dysbiosis and restoration of healthy gut homeostasis have 
become important therapeutic strategies to cure diseases.  
B. Functional entities that constitute gut homeostasis 
a. Gut microbiota 
i. Resilience and resistance to disturbance  
Resilience of gut homeostasis reflects physiological stability, 
which is the ability to resist change in response to potentially 
perturbing forces(Levine and D’Antonio 1999). Taxonomic and 
functional diversity of gut microbiota are crucial in conferring 
resilience in gut homeostasis(Lozupone et al. 2012). Low microbial 
diversity correlates with obesity(Yatsunenko et al. 2012; Ley et al. 
2006), Inflammatory Bowel Disease (IBD)(Ben P Willing et al. 2010), 
and recurrent Clostridium difficile-associated diarrhea (CDAD)(Chang 
et al. 2008). It is still unclear if there is direct cause-consequence 
relationship between microbial diversity and resilience.  
Mirroring principles in ecology, Catherine A. Lozupone, et al, 
proposed competition and feedback loops as mechanisms for resilience 
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in gut microbiota(Lozupone et al. 2012). Competing with commensal 
bacteria for the same resources, such as nutrients, is associated with 
pathogen colonization and eradication. For example, Citrobacter 
rodentium exhibits optimal growth on monosaccharides. Bacteroides 
thetaiotaomicron directly competes with C. rodentium for 
monosaccharides and decreases load of C. rodentium when only 
simple sugar diet is available(Kamada et al. 2012). Thus, nutrient 
competition can regulate C. rodentium growth and resistance against 
external invasion in the gut. Positive and negative feedback loops can 
drive primary succession and confer resilience in gut 
homeostasis(Lozupone et al. 2012). For example, microbial 
perturbation can cause negative or positive feedback loop which is 
delicately manipulated by metabolic activities and host pathways. 
Pathogen infection induced diarrhea or constipation may be regulated 
by changes in microbial metabolites and their downstream host 
pathways to control gut retention time and mucin secretion. Changes 
of gut retention time can regulate pathogen colonization and 
eradication. Although gut homeostasis can resist perturbation to some 
extent, the unhealthy state of microbial community could be also very 
stable and persist for years or decades, which partially explains why 
some Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease 
(IBD) cases are recurrent and hard to cure. The therapeutic strategy is 
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focused on increased resilience of healthy microbiota and decreased 
resilience of unhealthy microbiota. 
ii. Gut-liver axis  
Liver is the major organ that metabolizes microbial products 
and toxin derived from gut microbes. Nutrients and metabolites are 
transported into liver via two afferent pathways, the hepatic portal 
system and the lymphatic system(Björkholm et al. 2009). Liver is the 
processing center and regulates the homeostasis of cholesterol, bile 
acids, choline metabolites, vitamins, lipids, phenols and short chain 
fatty acids(Nicholson et al. 2012). The  metabolites are then 
transported from the liver to the intestine via the efferent bile ducts to 
close the loop and define the enterohepatic circulation(Björkholm et al. 
2009). Mammalian-microbial co-metabolisms takes place in the gut-
liver axis. An example is bile acids, which are primarily derived from 
cholesterol catabolism and become conjugated bile acid in the 
liver(Nicholson et al. 2012). The primary bile acids are transported as 
bile into intestines, where microbial enzymes help primary bile acids 
transform into secondary bile acids through dehydroxylation, 
dehydrogenation, and deconjugation(Shapiro et al. 2014). Intestinal 
bacteria can transform about 5-10% bile acids through degradation. It 
is worthy to be noted that secretion and reabsorption of bile acids 
through enterohepatic cycle take place by about eight times a day. It 
has been demonstrated that germ-free mice lack secondary bile 
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acids(Narushima et al. 1999) implicating the role of gut bacteria for 
the conversion of primary to secondary bile acid.  
The liver is the largest immune organ and plays an important 
role in immune response to gut derived nutrients and other signals. 
Alteration of gut microbiome and disruption of gut barrier function 
may promote translocation of microbes into the portal circulation and 
increase bacterial load in the liver(Szabo et al. 2010). Damage of liver 
function impairs clearance of microbes from blood resulting in 
activation of nonmucosal immune responses(Arvaniti et al. 2010; 
Szabo 2015). Fibrosis and cirrhosis can cause multiple symptoms, 
such as portal hypertension, spleen enlargement, intestinal damage, 
and abnormal vascular channels, and impair the portal circulation,  
leading to increased risks of systemic infections of gut-derived and 
blood-borne pathogens(Arvaniti et al. 2010; Szabo 2015).   
iii. Gut-brain axis 
Preclinical evidences suggested that gut-brain interactions are 
implicated in modulation of peripheral enteric and central nervous 
systems. Alteration of gut microbiome is associated with brain 
disorders, such as autism, Parkinson’s disease, depression and 
impaired cognition(Mayer, Tillisch, and Gupta 2015). It is largely 
unknown how gut microbiota modulate nervous system. The 
bidirectional communication between gut and both central and 
peripheral nervous system involve microbial metabolites, immune 
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response, neurotransmitters, and the hypothalamic pituitary adrenal 
(HPA) axis(Carabotti et al. 2015).  The HPA axis plays a crucial role 
in modulating emotion or stress through neuro-immuno-endocrine 
mediators. For example, environmental stressors or inflammation can 
activate this system and induce release of cortisol, a stress hormone 
that affects many organs, including the brain(Carabotti et al. 2015).  
Recent studies by Hsiao and colleagues uncover a role of gut 
microbiota in modulating serotonin (5-hydroxytryptamine, 5-HT) 
biosynthesis(Yano et al. 2015). It suggests gut microbiota can directly 
regulate fundamental neurotransmitter 5-HT-related biological 
functions. Opioids as analgesic drugs can change transmission and 
perception of pain. However, it can also cause gastrointestinal 
symptoms, such as constipation, nausea, vomiting, and bloating. The 
study on the gut-brain axis may help elucidate mechanisms by which 
opioids modulate gut homeostasis.  
b. Metabolites 
Microbiome patterns and metabolome profiles can’t simply map or 
reflect each other. The metabolic consequences and potential, rather than 
microbial patterns, allow us to understand the functional microbiota(Ursell et 
al. 2014). Gut metabolites play a significant role in the crosstalk between gut 
microbes and host biological functions, such as the maturation of the host 
immune system(Nicholson et al. 2012) and protection against 
pathogens(Lawley and Walker 2013). Healthy microbiota produce the SCFAs 
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as carbon sources for the host, synthesize vitamins and essential amino acids, 
transform bile acids, produce neurotransmitters and modify 
xenobiotics(Heinken and Thiele 2015). Based on the importance of microbial 
metabolites and non-invasive characteristics, dietary intervention presents huge 
potential in therapeutic strategy.  
i. Bile acids 
Bile acids are typical metabolites that involve mammalian-
bacterial co-metabolism. After primarily produced by liver from 
cholesterol, bile acids are secreted as bile into intestine and 
transformed into secondary bile acids by gut microbes through 
dehydroxylation, dehydrogenation, and deconjugation(Shapiro et al. 
2014). Germ-free mice lack secondary bile acids and exhibit decreased 
bile acid diversity when compared with conventionally raised 
mice(Sayin et al. 2013). Bile acids play crucial roles in absorption of 
dietary fats and lipid-like vitamins, maintenance of intestinal barrier 
function, orchestration of endocrine signals, regulation of triglycerides, 
cholesterol, glucose and energy homeostasis(Brestoff and Artis 2013). 
Different bile acids can bind the G protein coupled receptor RGR5 and 
nuclear receptor farnesoid X receptor (FXR)(Pols et al. 2011; 
Vavassori et al. 2009). Activation of RGR5 and FXR can negatively 
regulate NFκB signaling pathway and lead to attenuated inflammation. 
Recent studies reveal that bile acids can mediate resistance to C. 
difficile infection and maintain healthy gut microbiota(Buffie et al. 
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2014). It has been demonstrated that administration of Clostridium 
scindens, a bile acid 7α-dehydroxylating intestinal bacterium, can 
enhance resistance to C. difficile infection, indicating secondary bile 
play an important role in protection against C. difficile. The 
intervention using secondary bile acids and/or related biosynthesis 
bacteria may contribute to therapeutic strategies.  
ii. Short chain fatty acids 
Short chain fatty acids (SCFAs) are bacterial fermentation 
products from plant-derived polysaccharide, an essential component of 
human diet. SCFAs serve as energy source and inhibit autophagy in gut 
epithelial enterocytes(Donohoe et al. 2011). SCFAs can directly 
modulate leukocytes, for example, enhance chemotaxis in neutrophils 
and increase cytolytic activity, inhibit histone deacetylases in 
macrophages and reduce proinflammatory cytokines production, 
modulate methylation of the conserved non-coding sequence 1 (CNS1) 
in the FoxP3 locus and leads to regulatory T cells (Tregs) proliferation 
(Shapiro et al. 2014; Furusawa et al. 2013; P. M. Smith et al. 2013). 
SCFAs propionate and butyrate can modulate brain function, mood, and 
behaviors via gut-brain neural circuits (Burokas et al. 2015; De Vadder 
et al. 2014).  
iii. Long chain fatty acids 
Long chain fatty acids (LCFAs) are derived from dietary oils. A 
variety of LCFAs exhibit association with health risks and benefits. The 
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number of double bonds in LCFAs can affect cellular membrane fluidity 
and stability. More double bonds in phospholipid fatty acids can lead to 
higher membrane fluidity. Gut microbiota can modulate LCFAs 
quantity and composition. For example, Bifidobacterium breve can help 
transform linoleic acids into conjugated linoleic acids (CLA), which can 
reduce hepatic triacylglycerol content in host metabolism and inhibit 
atherosclerosis(Toomey et al. 2006; Gudbrandsen et al. 2009).  Omega-
6 and omega-3 fatty acids are considered essential dietary fatty acids for 
mammals, because they are necessary for physiologic growth and 
function but animals are unable to synthesize them in adequate 
quantities. The long chain polyunsaturated fatty acids (PUFAs), 
including omega 3 fatty acids have been shown to decrease 
inflammatory response via NFκB inhibition. Compared to omega-3 
PUFAs, omega-6 PUFAs increased susceptibility to C. rodentium 
infection in mice. However, combination of omega-3 and omega-6 
PUFAs supplementary diet has been shown reduce C. rodentium 
induced inflammation and inhibit epithelial intestinal alkaline 
phosphatase-mediated detoxification of LPS, leading to increased 
mortality from C. rodentium infection(Ghosh et al. 2013).  
iv. Polysaccharides 
Polysaccharides are not only structural components of gut 
microbes, but function as mediators between host-microbial interactions. 
The capsular polysaccharide A (PSA) of the commensal Bacteroides 
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fragilis can modulate Th1/Th2 balance and direct lymphoid 
organogenesis. Intestinal dendritic cells can present PSA to activate 
CD4+ cells and induce appropriate cytokine production (Mazmanian et 
al. 2005; Mazmanian, Round, and Kasper 2008). PSA of B. fragilis can 
promote tolerant immune response via induction of FoxP3+ regulatory 
T cells and suppression of Th17 cell reaction in a TLR2-dependent 
manner(Round et al. 2011). PSA-deficient B. fragilis are unable to 
colonize gut mucosal surface in germ free mice due to robust Th17 
immune response(Round et al. 2011). So, PSA plays an important role 
in modulating gut homeostasis and host-microbial symbiosis. 
v. Vitamins 
Vitamins are important nutrients that modulates multiple 
cellular and organ functions. It has been well demonstrated that vitamin 
biosynthesis and metabolism rely on commensal intestinal microbiota. 
Vitamin A and its metabolite retinoic acid (RA) are critical in 
maintenance of epithelial integrity and gut microbiota 
diversity(Rojanapo, Lamb, and Olson 1980; Cha et al. 2010). Retinoic 
acid can regulate immune homeostasis by inducing histone acetylation 
of FoxP3 promoter(Kang et al. 2007). Interestingly, RA is required in 
the promotion of CD4+ T cell effector responses to infection, mucosal 
vaccination, T cell polarization shift from Th1/Th17 to Th2 and B cell 
isotype switch to IgA and IgE (Tokuyama and Tokuyama 1996; Hall, 
Cannons, et al. 2011). Vitamin A deficiency can cause impaired 
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humoral and cellular immune response, increased susceptibility to 
infection, and mucosal damage(Hall, Grainger, et al. 2011). Therapeutic 
administration of vitamins serves as a good way in modulating gut 
homeostasis. 
c. The gut epithelium 
The gut has a huge surface area (400 sq m), which is necessary to 
absorb nutrients and transport water, and the gut epithelial barrier contains 
only a single layer of epithelium, which prevents against microbial invasion 
and promotes host-microbial interaction(Lozupone et al. 2012). The intestinal 
epithelium is composed of a variety of histological and functional entities, 
such as enterocytes, goblet cells, Paneth cells, microfold (M) cells and 
enterochromaffin (ECC) cells. Goblet cells continuously produce and secrete 
mucins which form a thick mucus layer. Paneth cells can sense microbiota via 
MyD88-dependent TLRs and release antimicrobials such as defensins and 
lectins(Vaishnava et al. 2008). M cells facilitate the transport of microbes and 
particles from gut lumen to immune cells in the underlying Peyer’s patches, 
where antigens can be transported to antigen presenting cells, such as 
dendritic cells (DC). Unlike their neighboring cells, M cells are not covered 
by the thick mucus layer. This unique property allows them to facilitate 
ingestion of antigen from intestinal lumen. The epithelial tissue functions as a 
selectively permeable barrier by delicate regulation of the tight junctions, 
which join together intestinal epithelial cells (IECs). ECCs are a type of 
enteroendocrine and neuroendocrine cells that secrete various hormones, like 
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serotonin, in response to chemical, mechanical or pathological stimuli from 
the intestinal lumen. Additionally, DCs can project dendrites through the 
intestinal barrier and directly sample antigens in lumen. DCs can then deliver 
pathogen to local T cell areas, or mesenteric lymph nodes (MLN) through 
lymphatic circulation. Besides DCs, that constitutively traffic, the lamina 
propria beneath the epithelium also include: mucosal macrophages, T cells, 
and IgA-secreting B cells.  
d. The immune system 
Intestinal immune defense is designed to allow immune surveillance of 
pathogens, while it operates with minimal disruption to the absorptive 
function of the gut(Hooper, Littman, and Macpherson 2012). In normal hosts, 
commensal bacteria activate homeostatic response by host immune system 
that permit coexistence with potential toxic bacterial products through down-
regulating bacterial receptors, inhibiting pathogenic innate and adaptive 
immune responses, inducing antimicrobial peptides, and promoting mucosal 
barrier repair(Sartor 2008). Gut microbiota exert profound effects on the 
maturation and function of the immune system, thus it influences immune-
mediated diseases, such as inflammatory bowel disease (IBD)(Morgan et al. 
2012). Although the casual role in multifactorial autoimmune diseases is still 
outstanding, host-microbial interaction is implicated in the development of 
autoimmune diseases, such as type 1 diabetes (T1D), rheumatoid arthritis 
(RA), multiple sclerosis (MS)(Ruff and Kriegel 2015). Understanding 
pathogenesis of immune-mediated disease might create potential cures.  
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Pattern recognition receptors mediated innate immune recognition of 
the microbiota promotes maturation of immune system and host-microbial 
symbiosis(Chu and Mazmanian 2013). Toll-like receptors (TLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are 
sensors of microbes(Wells et al. 2011; Artis 2008). Cytokines, chemokines, 
neurotransmitters, mammalian and bacterial metabolites are key molecular 
mediators in modulation of immune homeostasis(Marchiando, Graham, and 
Turner 2010; Artis 2008; de Jonge 2013). Toll-like receptor-4 (TLR4) 
signaling in the intestine is required for intestinal response to epithelial injury 
and inhibit bacterial translocation in DSS induced acute colitis in mice(Fukata 
et al. 2005). An increase in gram-negative bacterial translocation into 
mesenteric lymph nodes (MLN) was seen in TLR4-/- mice more frequently 
than wild-type littermates given DSS(Fukata et al. 2005). Innate immune 
response is necessary for induction of antibody response to trivalent 
inactivated influenza vaccine (TIV) in humans(Oh et al. 2014). TLR5 
mediated sensing of the gut microbiota impacts the magnitude of antibody 
response to the TIV by promoting plasma cells differentiation and increasing 
antibody titers(Oh et al. 2014).  
Humoral immunity also plays an important role in gut homeostasis. 
Secretory IgA from gut epithelial cells is concentrated in the outer layer of 
colonic mucus and interacts with gut microbes(Rogier et al. 2014). IgA-
mediated targeting of bacteria helps transport of commensals to Peyer’s patch 
and promotes immune surveillance of dendritic cells(Rol et al. 2012). 
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Antinuclear antibodies are signature of generalized autoimmune disease and 
aberrant adaptive immune system can cause immune-mediated tissue 
damage(von Mühlen and Tan 1995; William et al. 2002). Van Praet, et al. 
demonstrated that neonatal colonization of gut microbiota is associated with 
generalized autoimmune disease in adult life(Van Praet et al. 2015). Non-
specific innate immune and specific adaptive immune interactively respond to 
virulent bacteria in gut(Collins et al. 2014). Intestinal infection induced IgG 
can selectively target virulent factors and bind pathogenic bacteria in gut, 
leading to pathogen elimination and host survival (Kamada et al. 2015). 
e. Host genetics  
Host genetic variation can directly cause significant alteration in gut 
microbiome and host-microbial interaction(Spor, Koren, and Ley 2011; Leifer 
et al. 2014). By using the well-powered twins study, Goodrich JK, et al, 
compared monozygotic (MZ) than dizygotic (DZ) twin pairs, and found 
microbiome are more highly correlated within MZ than DZ twin pairs, 
indicating host genetics can influence gut microbiome (Goodrich et al. 2014). 
Particularly, they found some microbes are more influenced by host genetics 
and considered heritable microbes. Interestingly, one of the cultured strains, 
Christensenella minuta, is more abundant in lean twins than obese ones. C. 
minuta can shape phenotype by leading to thinner body weight after adding C. 
minuta in obese mouse.  It is still unknown what variation of genetics is 
associated with changes of heritable microbes, such as C. minuta. It has been 
demonstrated that a single gene, MEFV, encoding pyrin, associates with 
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changes of gut microbiota and leads to familial Mediterranean fever 
(Khachatryan et al. 2008; Ting, Kastner, and Hoffman 2006).   
C. Variable factors that affect gut homeostasis 
a. Age 
Infants are born from a nearly sterile environment and expose to 
microbes results in their establishment of gut microbiota thereafter. During the 
first three years of life, bacterial diversity increases along with age and 
gradually reach a stable adult-like profile(Yatsunenko et al. 2012). Gut 
microbiome become more stable throughout adulthood(Yatsunenko et al. 
2012). Although aging as a multidimensional process is poorly defined, the 
physiological alterations along with aging process affect gut 
microbiome(Nicholson et al. 2012). Gut microbiome of infants exhibit high 
levels of Clostridium leptum and Clostridium coccoides, while Escherichia 
coli and Bacteroidetes were highly represented in elderly subjects(Mariat et 
al. 2009). The ratio of Firmicules to Bacteroidetes is 0.4, 10.0 and 0.6 in 
infants, adults and elderly individuals respectively(Mariat et al. 2009). Elderly 
individuals are accompanied with a broad range of medical challenges, such 
as increased risk of infectious diseases, cancers, cardiovascular disease, 
Parkinson’s disease and Alzheimer’s disease. Rapid progress has been 
ongoing in cellular and organism levels of physiological function and 
neuroimmune changes in terms of aging process(Lynch, Jeffery, and O’Toole 
2015). Age as a variable factor is inevitable and deeply involved in the 
interaction between host-microbes.  
19 
 
b. Natural birth vs. Caesarean section  
Infants born vaginally and born via Cesarean section exhibit 
differential initialization of gut microbiota(Dominguez-Bello et al. 2010). 
Naturally born infants acquire their mother’s vaginal microbiota, while C-
section babies establish microbial communities resembling skin microbiota. It 
has been demonstrated that C-section links to higher risk of childhood 
diseases, such as obesity, asthma, and other immune-mediated 
disorders(Leung et al. 2015; Mueller et al. 2014; Francis et al. 2014). 
Correlations have been noted in mice born by C-section are more anxious and 
exhibit symptoms of depression(Reardon 2014). A large cohort study of 
11096 mother-infant pairs gives evidence that children born by C-section may 
have a higher risk of cognitive and motor development delay at age 9 
months(Khalaf et al. 2015). Delivery mode affects microbiome colonization 
early in life and may cause lifelong changes in physiological development and 
mental health examples of these disease states. 
c. Pregnancy status 
It has been well known that pregnancy involves significant changes in 
immune and metabolic syndromes. These immune and metabolic changes are 
never alone. Pregnancy status can also mediate changes in microbial patterns 
and lead to differential functional consequence. In the Koren, et al. study of 91 
pregnant women, gut microbiota exhibited differential profiles from first (T1) 
to third (T3) trimesters, with an increase of Proteobacteria and Actinobacteria 
with a decrease in richness(Koren et al. 2012). T3 microbiota can cause 
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greater inflammatory response when compared to T1(Koren et al. 2012). T3 
microbiota can induce greater adiposity and insulin insensitivity in germ free 
mice, when compared with T1 microbiota(Koren et al. 2012).  
d. Diet  
The human gut microbiota act as processing center of nutrition and 
vitamins for host intestinal absorption(David et al. 2014; G. D. Wu et al. 
2011). On one hand, gut microbiota are rapidly and reproducibly shaped by 
diet intake. On the other hand, gut microbiota exploit counteractive efforts on 
nutrition consuming and human health. High-fat diet can shape distinct 
signatures of host-microbial metabolome and gut microbiome in mice(Walker 
et al. 2014). Gut microbiota from twins discordant for obesity can modulate 
metabolism in mice and induce marked weight gain in obese microbiota 
recipient mice when compared to lean microbiota recipient(Ridaura et al. 
2013). Malawian twin pairs discordant for kwashiorkor, a severe acute 
malnutrition induced by inadequate nutrition intake, exhibit distinct signatures 
in gut microbiome(M. I. Smith et al. 2013). The combination of Malawian diet 
and kwashiorkor microbiome can induce kwashiorkor-like weight loss in 
recipient gnotobiotic mice(M. I. Smith et al. 2013). Diet intervention has been 
shown to be an effective method in treating human diseases, such as obesity 
and kwashiorkor(Zhao 2013; Garrett 2013). 
There are epidemiological evidence that supports insufficient exposure 
to dietary and microbial metabolites is associated with increased incidence of 
immune-mediated diseases such as allergies, asthma, and autoinflammatory 
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diseases in Western countries(Thorburn, Macia, and Mackay 2014; Lukens et 
al. 2014). Retinoic acid, a vitamin A metabolite, can shape early intestinal 
response and attenuate inflammation by modulating mucosal T helper cell 
response and promote IL-22 production by γδ T cells and innate lymphoid 
cells(Mielke et al. 2013). Dietary compounds derived from cruciferous 
vegetables such as broccoli can activate the aryl hydrocarbon receptor (AhR), 
which play an important role in intraepithelial lymphocytes (IELs) 
maintenance in the intestinal epithelium and promote normal intestinal 
immune function(Li et al. 2011). SCFAs, such as acetate, propionate, and 
butyrate, are derived from dietary fiber and play a crucial role in gut 
homeostasis and immune tolerance(Thorburn, Macia, and Mackay 2014). By 
crossing the placenta or delivery via breast milk, SCFAs can also influence 
gene expression and the development of the immune system of the developing 
fetus(Thorburn, Macia, and Mackay 2014). 
e. Xenobiotics  
Morphine metabolism presents a fashion of host-microbial interaction 
(Stain-Texier, Sandouk, and Scherrmann 1998). The morphine metabolic 
pathway is primarily focused on glucuronidation to morphine 3-glucuronide 
(M3G) and morphine 6-glucuronide (M6G) in the liver(Pacifici et al. 1982). 
Though M3G exhibits no analgesic effect, M6G is more potent than 
morphine(Frances et al. 1992). M6G and M3G can be hydrolyzed by β-
glucuronidase in both intestinal mucosal cells and gut bacteria, and 
subsequently reabsorbed as morphine(Koster, Frankhuijzen-Sierevogel, and 
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Noordhoek 1985; Hawksworth, Drasar, and Hill 1971; Walsh and Levine 
1975). Anaerobes, such as bacteroides and bifidobacteria, are major sources of 
β-glucuronidase (Walsh and Levine 1975). Since the β-glucuronidase 
mediated hydrolysis is dependent on the bacterial composition of the gut, 
changes of gut microbiota may affect the rate and extent of the hydrolysis of 
morphine glucuronide. Diet has been shown to significantly influence the 
intestinal bacterial β-glucuronidase activity(Reddy, Weisburger, and Wynder 
1974). The fecal microbial β-glucuronidase activity in human subjects 
consuming Western high meat diet is higher when compared to nonmeat 
diet(Reddy, Weisburger, and Wynder 1974). However, it remains unknown 
how alteration of gut microbiota can affect β-glucuronidase activity and 
subsequent hydrolysis of morphine glucuronide 
Host-microbiome metabolic interaction affects human drug 
metabolism significantly(Clayton et al. 2009). Clayton, et al, observed that 
high urinary level of p-cresol sulfate produced by certain gut bacteria is 
correlated to low urinary ratio of sulfated to glucuronidated acetaminophen, a 
wide used analgesics(Clayton et al. 2009). Further study conducted by the 
same group demonstrated that the host-gut microbial metabolic interaction 
leads to modifications of major xenobiotic-metabolizing cytochrome enzymes 
and alteration of bile acid metabolites(Claus et al. 2011).  
Intestinal microbiota not only directly participate in xenobiotic 
metabolism in gut, but regulate xenobiotic metabolism in the liver, which is 
the central organ for xenobiotic metabolism. Xenobiotic metabolism in the 
23 
 
liver is regulated by nuclear receptor (NR), including Constitutive Androstane 
Receptor (CAR) and the Pregnane X receptor (PXR)(Meyer 2007). Bjorkholm 
et al. demonstrate that microbiota can regulate liver gene expression and alter 
xenobiotic metabolism by inhibiting CAR and PXR function (Björkholm et al. 
2009). Germ free mice exhibit higher efficient xenobiotic metabolism and 
undergo 35% shorter time of anesthesia when compared to conventional 
raised mice following pentobarbital treatment(Björkholm et al. 2009). 
Innate immunity links to xenobiotic metabolism and is implicated with 
host detoxification. TLR2 signaling can regulate gene expression in 
xenobiotic metabolism, such as multidrug transporter ABCB1/multidrug 
resistance (MDR)1 p-glycoprotein (p-gp)(Frank et al. 2015). TLR2-mediated 
synthesis and activation of ABCB1/MDR1 p-gp in murine and human 
CD11b+-myeloid cells functionally preserve drug efflux activity, leading to 
protection against chemotherapy-induced cytotoxicity(Frank et al. 2015). This 
finding suggests that targeting TLR2 is a novel therapeutic approach in 
modulating side effects of xenobiotics, such as chemotherapy-induced 
intestinal mucositis.  
It has been demonstrated that the xenobiotic sensor, pregnane X 
receptor (PXR) and Toll-like Receptor 4 (TLR4) play crucial roles in 
modulating gastrointestinal barrier function and xenobiotic toxicity(Venkatesh 
et al. 2014).  Commensal bacteria-derived metabolite, indole 3-propionic acid 
(IPA), can regulate gastrointestinal permeability and inflammation, and 
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protects against indomethacin-induced intestinal injury in a PXR and TLR4 
dependent manner(Venkatesh et al. 2014).  
Antibiotics usage in early life can cause profound perturbation to gut 
microbiome and lead to long-term dysbiosis, which links to higher risk of 
childhood disorders, such as childhood obesity, autism and type 1 diabetes 
(T1D)(Mueller et al. 2014; McDonald et al. 2015; Benjamin P Willing, 
Russell, and Finlay 2011). Alteration of the gut microbiome caused by 
antibiotics can lead to shifts of gut metabolome, which increased 
susceptibility to opportunistic infections, such as Clostridium difficile(Theriot 
et al. 2014; Börnigen et al. 2013). Long term studies in mice and pigs given 
sub-therapeutic dose of antibiotics found profound shifts in gut microbiome 
can cause increased abundance of SCFAs and higher host adiposity(Cho et al. 
2012; H. B. Kim et al. 2012). 
f. Infections 
Commensal bacteria, such as Enterococcus faecium and Enterococcus 
faecalis, colonize the gastrointestinal tract and are basically non-
pathogenic(Vouloumanou et al. 2009). However, Enterococci with tolerance 
to environmental stress and antibiotics can cause clinical infections in elderly 
and immunocompromised patients(Leanti La Rosa et al. 2013). There is no 
clear evidence has been found explains the ecological success of these 
infectious disease causing strains.  
Pathogen bacteria colonization and invasion always accompany by 
collapse of host homeostasis by dysregulating immune response, disrupting 
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gut barrier function and disturbing commensal microbiome. Citrobacter 
rodentium is a natural mouse pathogen that models intestinal infection by 
Escherichia coli in humans and causes attaching and effacing (A/E) lesions 
and colonic hyperplasia(Puente et al. 2004). C. rodentium colonization 
depends on virulence factor-mediated adhesion and provoke inflammation, 
which further disrupts gut microbiota and promotes the outgrowth of 
pathogenic bacteria (Lupp et al. 2007). Dextran sodium sulfate (DSS) 
chemically induced intestinal inflammation causes microbiota changes that 
resembles enteropathogenic infection(Lupp et al. 2007). Regulation of the 
virulence factor-mediated colonization and commensal-driven pathogen 
eradication may be potential therapeutic strategies. 
It is worthy to be noted that bacteria might not be the only organisms 
that can manipulate microbiota to cause diseases, viruses have been shown to 
promote virus replication and systemic pathogenesis by disrupting 
microbiota(Kuss et al. 2011). In an infectious murine model of early HIV 
infection, EcoHIV can cause bacterial translocation, suggesting intestinal 
microbial dysbiosis might contribute to early HIV pathogenesis in the 
gut(Sindberg et al. 2014). Clinical studies show that HIV-1 infection induces 
intestinal microbiome alteration, mucosal and systemic immune activation, 
microbial translocation and endotoxemia in human patients(Dillon et al. 
2014). The extent of gut microbial dysbiosis correlates with kynurenine levels 
and IL-6 plasma concentration, two established markers of disease 
progression(Vujkovic-Cvijin et al. 2013). 
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2. OPIOIDS MODULATION OF GUT HOMEOSTASIS 
A. Opioids and opioid receptors 
a. Opioids 
Opioids refer to a large group of compounds and chemicals that 
share the characteristics of opium(Ninković and Roy 2013). Synthetic 
opioids resemble morphine in pharmacological effects(Degenhardt et al. 
2013). Opioids are powerful analgesics being widely prescribed clinically, 
and as such, their use has a great impact on a large percent of world 
population(Docherty, Jones, and Wallace 2011). However, their clinical 
use has been limited by several serious adverse effects such as addiction, 
immunosuppression, and adverse gastrointestinal (GI) symptoms(Juurlink 
and Dhalla 2012; Gomes et al. 2011; Docherty, Jones, and Wallace 2011; 
Hilburger et al. 1997). Opioids can induce other CNS effects that include 
sedation, euphoria, and dysphoria(Coetzee 2013). There are 
epidemiological evidences that support  higher mortality among older 
adults with opioid use disorders(Larney et al. 2015). Mortality rates from 
dependent opioids users are approximately 15 times higher than that of 
age- and sex-matched control subjects(Degenhardt et al. 2011). 
b. Opioid receptors 
Opioid analgesics can exert their pharmacological effects through 
binding to specific cellular receptors (i.e., µ-, κ-, and δ- opioid receptors) 
and alter the transmission and perception of pain(Chan 2008). Most of the 
clinical effects of opioids are µ receptor dependent(Ninković and Roy 
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2013). The clinical effects of opioids vary between the µ opioid receptor 
agonists (e.g., morphine, hydromorphone), partial µ agonists (e.g., 
buprenorphine), and agonist-antagonists (e.g., butorphanol)(Epstein and 
Dabvp 2013). While primary pharmacological effects of opioids are 
dependent on the distribution of opioid receptors in central nerve system, 
opioid receptors are also expressed in the peripheral nervous system and 
the gastrointestinal tract (GI), such as in the myenteric plexus of the 
enteric nervous system (ENS)(Farzi et al. 2015). In addition, opioid 
receptors are also expressed by the cells of the immune system such as T 
cells, B cells and macrophages(Ninković and Roy 2013; Sabita Roy et al. 
2011). Thus, activation of opioid receptors not only affects perception of 
pain, but induces a variety of side effects attributing to regulation of neuro 
and immune systems. 
B. Opioids and diseases 
a. Opioids induce sepsis 
Morphine treatment has been shown to cause lethal gut-derived 
sepsis in mice(Babrowski et al. 2012; Hilburger et al. 1997). The sepsis 
caused by morphine treatment are implicated with disruption of gut barrier 
function, higher bacterial translocation, increased bacterial virulence 
expression, and dysregulated immune response (Banerjee et al. 2013). 
Chronic morphine administration can directly activate Pseudomonas 
aeruginosa virulence expression and lead to lethal gut-derived sepsis in 
mice(Babrowski et al. 2012). Banerjee, et al. have demonstrated that 
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chronic morphine treatment induced severe inflammation and 
exacerbation of septicemia is mediated through miR-146a 
regulation(Banerjee et al. 2013). 
b. Opioids increase susceptibility of infectious diseases  
Opioids induce immunosuppression and bowel dysfunction leading 
to increased susceptibility to bacterial and opportunistic infections(Mora et 
al. 2012; Ross et al. 2008; MacFarlane et al. 2000). For instance, morphine 
increases susceptibility to Streptococcus pneumoniae lung infection by 
impairing host innate immune response(J. Wang et al. 2005). There are 
clinical evidences that support opioid administration is associated with a 
greater risk of Clostridium difficile infection(Mora et al. 2012; D. L. 
Keller 2013). Opioids are also known to exacerbate viral pathogenesis. For 
example, morphine together with HIV-1 tat can regulate tight junction and 
modulate blood-brain barrier permeability, which is correlated with a 
greater risk of developing HIV dementia in opiate using HIV-1 patients 
(Mahajan et al. 2008). Neuropathogenesis of the simian immunodeficiency 
virus (SIV) infection in rhesus macaques can be exaggerated by morphine 
treatment(Bokhari et al. 2011). It has been demonstrated in a HIV-1 model 
of co-infection with pneumococcal pneumonia, morphine potentiates 
neuropathogenesis through modulation of toll-like receptors in microglial 
cells(Dutta et al. 2012). In order to better study effects of morphine on 
early HIV pathogensis in gut, Sindberg, et al, have established a mouse 
model of EcoHIV infection following opioids treatment(Sindberg et al. 
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2014). In this infectious murine model, EcoHIV infection with opioid 
treatment can induce bacterial translocation, intestinal damage and 
proinflammatory immune response, resembling effects of opioids on early 
HIV pathogenesis in the gut(Sindberg et al. 2014). 
c. Opioids and wound healing  
Opioids play an important role in relief of chronic pain and post-
surgical pain(Horn et al. 2002). Medical prescription of opioids in terminal 
patients is implicated with a greater risks of decubitus ulcers and bacterial 
infections(Egydio et al. 2012). Martin, et al. found that chronic morphine 
treatment is implicated with delayed wound healing by inhibiting LPS-
induced angiogenesis and immune cell recruitment to the wound site(J. L. 
Martin, Charboneau, et al. 2010; J. L. Martin, Koodie, et al. 2010). A well-
powered clinical trial shows that naltrexone, an opioid antagonist, can 
promote mucosal healing in active Crohn’s disease(J. P. Smith et al. 
2011). Topical treatment of naltrexone can also improve wound healing in 
type 1 diabetes rats(Immonen et al. 2013). Opioids induced delayed 
wound healing may be implicated with the unrepairable state of intestinal 
barrier dysfunction following morphine treatment.   
C. Opioids and gut homeostasis 
a. Opioids modulate intestinal function  
The primary functions of gastrointestinal tract includes digestion, 
absorption, secretion, motility, immune surveillance and tolerance(Leppert 
2015). Opioid administration is associated with multiple gastrointestinal 
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syndromes, such as constipation, leaky intestinal barrier function, bloating, 
nausea and vomiting(Harari, Weisbrodt, and Moody 2006). Morphine are 
known to inhibit protective mucus and bicarbonate secretion from the 
intestinal epithelium and human bronchi(Rogers and Barnes 1989). Opioids 
treatment can attenuate intestinal motility by inhibiting coordinated myenteric 
activity, and cause delayed transit time and a greater risk for bacterial 
translocation(Balzan et al. 2007). Morphine induced prolongation of intestinal 
transit time increases the intraluminal bacterial count and augments bacterial 
translocation(Erbil et al. 1998). Morphine can attenuate epithelial immune 
function by decreasing cytokines secretion from gut epithelium in response to 
enteric infections of entero-adherent Escherichia coli O157:H7 and entero-
invasive Salmonella enterica serovar Typhimurium(Brosnahan et al. 2014). 
There are clinical evidences that support that opioid administration leads to 
dysregulated immune response, increased intestinal barrier permeability, 
bacterial translocation, higher risk of enteric infection, and gut-derived 
sepsis(Mora et al. 2012; Babrowski et al. 2012).  
b. Opioids impair gut epithelial integrity 
Disruption of gut epithelial integrity has severe consequences 
including bacterial translocation from the gut leading to proinflammatory 
immune response(Schulzke et al. 2009). Well organized transmembrane and 
paracellular tight junction proteins in polarized intestinal epithelium facilitate 
their selective barrier function. Meng et al. demonstrated that morphine can 
disrupt intestinal barrier function and damage tight junction protein 
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organization via modulation of myosin light chain kinase (MLCK) in a TLR 
dependent manner(Meng et al. 2013). Naltrexone, an opioid antagonist, has 
been shown to have therapeutic effect on mucosal healing in active Crohn's 
disease, indicating opioid receptors are implicated with maintenance of gut 
epithelial integrity(J. P. Smith et al. 2011).  
c. Opioids modulate immune systems  
Studies on modulation of immune systems by chronic opioid use and 
abuse have been well documented ever since 1996 and subsequent 
reviews(Sabita Roy and Loh 1996; Sabita Roy et al. 2011; Ninković and Roy 
2013; Hutchinson, Shavit, and Grace 2011).  It is well established that opioid 
receptors are expressed on cells of immune system, such as B cells, T cells, 
and macrophages(Eisenstein 2011). Thus, opioids exert their pharmacological 
effects not only as analgesics but regulators of immune function. Roy, et al, 
demonstrated that morphine suppresses macrophage colony formation in bone 
marrow and modulates NFκB activation in macrophages(Sabita Roy et al. 
1991; S Roy et al. 1998). Morphine produces immunosuppressive effects, 
attenuates T cell maturation, alters cytokine secretion, decreases production of 
protein mediators of energy metabolism, signaling, and cell structure 
maintenance in nonhuman primates(J. N. Brown et al. 2012). Morphine 
induced neuro-immune interaction causes direct intestinal functional 
consequences. Meng et al. demonstrated that morphine disrupts gut barrier 
function through TLR-dependent manner(Meng et al. 2013). Chronic 
morphine treatment inhibits innate immune response, decreases Th1 cytokine 
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production and T cell activation, shifts to Th2 differentiation, and reduces 
antibody production and MHCII expression, leading to a greater risk of 
opportunistic infection and impaired pathogen elimination(Sabita Roy et al. 
2011). 
d. Gap of knowledge: opioid modulation of gut microbiome and metabolome 
It has been well demonstrated that morphine treatment results in 
significant disruption in gut barrier function, leading to increased translocation 
of gut commensal bacteria(Meng et al. 2013; Das et al. 2011). The interaction 
of gut microbiota with host immune system is shown to be required to 
maintain the homeostasis of the mucosal immunity and preserve the integrity 
of the gut epithelial barrier(Hooper, Littman, and Macpherson 2012). 
However, it is unclear how opioids modulate the gut microbiome and 
metabolome. Current rapid progress in understanding of host-microbial 
interaction has redefined pathogenesis. Effects of morphine treatment on gut 
homeostasis in the context of bacterial or viral infections remain unknown. 
The study of morphine modulation of gut microbiome and metabolome will 
shed light on the effects of morphine on gut homeostasis and its role in the 
infectious disease scenarios. 
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CHAPTER 2 
OPIOID TREATMENT INDUCES DISTINCT 
MICROBIOME AND METABOLOMIC SIGNATURES 
 
INTRODUCTION 
Morphine is the gold standard for pain management. Opioids analgesics are 
frequently prescribed in the United States and worldwide(Docherty, Jones, and Wallace 
2011). However, serious side effects such as addiction, immunosuppression and 
gastrointestinal (GI) symptoms limit their use(Juurlink and Dhalla 2012; Gomes et al. 
2011; Docherty, Jones, and Wallace 2011; Hilburger et al. 1997). Alteration in gut 
microbiome has been shown to contribute to bowel dysfunction and gut barrier 
disruption(Buccigrossi, Nicastro, and Guarino 2013). It has been well studied that 
morphine can cause gastrointestinal symptoms such as constipation, nausea, vomiting, 
bloating, and gut barrier dysfunction(Leppert 2015). However, it is still unknown how 
opioids modulate gut flora and its homeostasis within the host. Approximately, 1013-1014 
bacterial communities inhabit human intestinal tract(Relman 2012). The symbiotic 
relationship between commensal gut microbiota and the host is to achieve a balanced, 
mutually beneficial state. (Hooper, Littman, and Macpherson 2012). Gut homeostasis is 
maintained by commensal bacteria, functional barrier, and tolerant immune system and 
conveys the state of resilience and resistance to external and endogenous factors. 
Disruption of gut homeostasis leading to microbial dysbiosis is associated with disease 
and is implicated in a variety of diseases, such as obesity, diabetes, autoimmune, allergic, 
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metabolic, inflammatory and infectious diseases (Gordon 2012; Sommer and Bäckhed 
2013).  
Recent rapid progress in metagenomics provides powerful tools to determine 
perturbation of the human microbiome as a contributor to diseases(Gordon 2012). 
Changes in composition or density of the microbiota is associated with higher 
susceptibility to a variety of pathogens and abnormal mucosal immune responses(Wells 
et al. 2011; Stecher and Hardt 2008). Taxonomic and functional diversity of gut 
microbiota are crucial in conferring resilience in gut homeostasis(Lozupone et al. 2012). 
Low microbial diversity correlates with obesity(Yatsunenko et al. 2012; Ley et al. 2006), 
Inflammatory Bowel Disease (IBD)(Ben P Willing et al. 2010), and recurrent 
Clostridium difficile-associated diarrhea (CDAD)(Chang et al. 2008). It is still unclear if 
there is direct cause-consequence relationship between microbial diversity and resilience. 
It has been shown in our laboratory and other research groups that morphine disrupts 
intestinal barrier function and induces bacterial translocation in mice. Use of opioids are 
associated with an increased risk of C. difficile infection(Mora et al. 2012). Morphine 
treatment has been shown to activate the virulent factors of Pseudomona and induce gut 
derived sepsis. We recently demonstrated that morphine inhibition of endotoxin tolerance 
leading to sustained sepsis is mediated through modulation of miR-146a(Banerjee et al. 
2013). Opioid exacerbation of gram-positive sepsis is rescued by IL-17A 
neutralization(Meng et al. 2015). It is not yet clear whether morphine treatment perturbs 
gut microbial homeostasis and thus resulting in increased growth of gut pathogenic 
bacteria and microbial translocation. 
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There are evidences suggesting that metabolites in gut play a significant role in 
the crosstalk between gut microbes and host biological functions, such as the maturation 
of the host immune system(Nicholson et al. 2012) and protection against 
pathogens(Lawley and Walker 2013). Disruption in bile acids metabolism is associated 
with  susceptibility to C. difficile infection(Buffie et al. 2014). Gastrointestinal barrier 
function can be regulated by intestinal symbiotic bacterial metabolites via the Xenobiotic 
Sensor PXR dependent TLR4 signaling(Venkatesh et al. 2014). Healthy microbiota 
produce the short chain fatty acids (SCFAs) as carbon sources for the host, synthesize 
vitamins and essential amino acids, transform bile acids, produce neurotransmitters and 
modify xenobiotics(Heinken and Thiele 2015). We have confirmed that morphine-
induced intestinal barrier dysfunction contributes to bacterial translocation(Meng et al. 
2013). However, it is still unknown how morphine treatment modulates composition and 
abundance of gut metabolites. Metabolomic analysis allow for the determination and 
identification of small molecular metabolites within the gut lumen thus profiling the 
functional status of the microbiome in (Marcobal et al. 2013). The current study therefore 
is focused on identification of distinctness in morphine-modulated gut microbiome and 
their functional consequence through metabolomics analysis. 
Host-microbiome metabolic interaction affects xenobiotics metabolism 
significantly(Clayton et al. 2009). Clayton, et al, demonstrated that the host-gut microbial 
metabolic interaction leads to modifications of major xenobiotic-metabolizing 
cytochrome enzymes and alteration of bile acid metabolites(Clayton et al. 2009; Claus et 
al. 2011). The morphine metabolic pathway is primarily through glucuronidation 
biotransforming to morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G) 
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in the liver(Pacifici et al. 1982). Though M3G exhibits no analgesic effect, M6G is more 
potent than morphine(Frances et al. 1992). M6G and M3G can be hydrolyzed by β-
glucuronidase in both intestinal mucosal cells and gut bacteria, and subsequently 
reabsorbed as morphine(Koster, Frankhuijzen-Sierevogel, and Noordhoek 1985; 
Hawksworth, Drasar, and Hill 1971; Walsh and Levine 1975). However, the role of the 
gut microiome in morphine metabolism and elimination is relatively unknown.  
The aim of the present study is to reveal the distinctness of gut microbiome and 
metabolome modulated by morphine. We characterize morphine-induced alteration of gut 
microbiome and metabolome in mice. Our results show that, when compared to placebo, 
morphine treatment induces decrease in microbial community diversity, and leads to 
distinct clustering and profiling of gut microbiome and metabolome. We establish that 
expansion of Enterococcus faecalis is a distinct feature associated opioid-induced gut 
microbiome alteration, and alteration in deoxycholic acid (DCA) and 
phosphatidylethanolamines (PE) associated with opioid-induced metabolomic changes. 
We find cross-correlation association between intestinal bacterial communities and 
functional metabolites. Furthermore, we determine an increased M3G/MS ratio in gut 
suggesting alteration of M3G deconjugating microbes may influence opioid metabolism 
and elimination. Collectively, these results reveal opioids-induced distinct alteration of 
gut microbiome and metabolome, may contribute to opioids-induced pathogenesis and 
morphine pharmacokinetics.  
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MATERIALS AND METHODS 
 
Experimental animals 
Pathogen-free C57BL/6J mice were obtained from the Jackson Laboratory (Bar 
Harbor, Maine, USA). All animals were housed in a specific-pathogen-free facility. All 
animal experiments were done in accordance with the Institutional Animal Care and Use 
Committee’s guidelines at the University of Minnesota (Protocol No. 1203A11091). All 
surgery was performed under isoflurane anesthesia, and all efforts were made to 
minimize suffering. 
 
Animal treatment 
Mice received morphine and pellet implantation method as described(Bryant et al. 
1988). Using this method, plasma levels of morphine are in the 0.6–2.0-microg/ml range 
(range seen in opioid abusers and patients on opioids for moderate to severe pain). 
Furthermore, this model is commonly used in the study of opiate dependence and 
addiction(Bryant et al. 1988). Briefly, placebo or 25 mg morphine or 30 mg naltrexone 
pellets (National Institutes of Health [NIH]/National Institute on Drug Abuse [NIDA], 
Bethesda, MD) were inserted in a small pocket created by a small skin incision on the 
animal’s dorsal side; incisions were closed using surgical wound clips (Stoelting, 9 mm 
Stainless Steel, Wooddale, IL). 
 
Fecal sample collection and DNA extraction 
Stool samples were collected into 1.7ml RNase/DNase-free tubes (Catalog #: C-
2170, Denville Scientific, Holliston, MA, USA) at time points accordingly. The fecal 
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samples were immediately frozen on dry ice and then stored at -80 °C; DNA extractions 
from fecal matters were carried out using the PowerSoil DNA isolation kit (Catalog #: 
12888-100, MO BIO Laboratories, Carlsbad, CA, USA). All extracted DNA samples 
were stored at -80°C until amplification. 
 
Quantitative real-time PCR amplification 
Fecal DNA samples (25 ng) were used as template for PCR amplification of the 
V4 region of the 16S rRNA gene. Degenerate primer sets were designed with Illumina 
index sequences on the 5 end of the reverse primer, which were specific to each fecal 
DNA sample and allowed for multiplexed sequencing. Primers also contained Illumina 
PCR primer sequences (reverse primer) and Illumina TruSeq Universal Adapter 
sequences (forward primers) for library creation. Primer sequences (16S-specific portion 
in bold) are Meta_V4_515F 
(TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGT
AA) and Meta_V4_806R 
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTC
TAAT). The indexing primers are as follows. This step adds both the index and the flow 
cell adapters. [i5] and [i7] refer to the index sequence codes used by Illumina. The p5 and 
p7 flow cell adapters are in bold. Forward indexing primer: 
ATGATACGGCGACCACCGAGATCTACAC[i5]TCGTCGGCAGCGTC; Reverse 
indexing primer: 
CAAGCAGAAGACGGCATACGAGAT[i7]GTCTCGTGGGCTCGG. PCR reactions 
are performed using KAPA HiFidelity Hot Start Polymerase. PCR 1 (using the 
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Meta_V4_515F/Meta_V4_806R primer pair): 95°C 5 minutes, 20 cycles (98°C 20 
seconds, 55°C 15 seconds, 72°C 1 minute), then hold at 4 °C. After the first round of 
amplification, PCR 1 products are diluted 1:100 and 5 ul of 1:100. PCR 1 is used in the 
second PCR reaction. PCR 2 (using different combinations of forward and reverse 
indexing primers): 95°C 5 minutes, 10 cycles (98°C 20 seconds, 55°C 15 seconds, 72°C 
1 minute), then hold at 4°C.  
 
DNA sequencing  
The genomic DNA sequencing were performed by using Illumina MiSeq at the 
University of Minnesota Genomic Center (UMGC). Pooled, size-selected samples were 
denatured with NaOH, diluted to 8 pM in Illumina’s HT1 buffer, spiked with 15% PhiX, 
and heat denatured at 96C for 2 minutes immediately prior to loading. A MiSeq 600 cycle 
v3 kit was used to sequence the sample. Nextera adapter sequences for post-run trimming  
Read 1: 
CTGTCTCTTATACACATCTCCGAGCCCACGAGACNNNNNNNNATCTCGTATG
CCGTCTTCTGCTTG 
Read 2: 
CTGTCTCTTATACACATCTGACGCTGCCGACGANNNNNNNNGTGTAGATCTC
GGTGGTCGCCGTATCATT 
 
Sequence processing and analysis 
Microbial operational taxonomic units (OTUs) and their taxonomic assignments 
were obtained using default settings in QIIME version 1.8.0 by reference-mapping at 
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97% similarity against representative sequences of 97% OTU in Greengenes (release 
GG_13_8), following which chimeric sequences were removed from subsequent 
analyses. Sequences showing 97% or greater similarity were clustered into operational 
taxonomic units (OTUs) using the USEARCH method and representative sequences were 
assigned taxonomies using the RDP classifier. Principal coordinate analysis (PCoA) of 
weighted UniFrac phylogenetic distances between communities, and Phylogenetic 
Diversity estimates were performed using the scripts in QIIME 1.8.0. To perform 
bootstrap, jackknife, and rarefaction analyses, the OTU table was rarefied at the cutoff 
value of 31000 sequences per sample. Bacterial taxa were arcsine-square-root 
transformed to stabilize variance and reduce heteroscedasticity. Differences in mean 
proportions of taxa were analyzed using Microbiome-Wide Association Study (MWAS) 
packages in R 3.2.1, the results of which were corrected for multiple testing using the 
false discovery rates (FDR) adjustment. FDR values <0.05 were considered significant. 
(Hu Huang and Dan Knights. (2015). MWAS R package. URL: 
https://github.com/danknights/mwas). 
 
Microbiome phenotype analysis 
Microbiome based functional phenotype analysis were performed by using 
BugBase software package, which relies on other software, such as PICRUSt and QIIME. 
(Tonya Ward and Dan Knight. URL: https://github.com/danknights/bugbase) 
 
LC-MS analysis of fecal extracts 
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The method for LC-MS analysis of fecal extracts was based on previous study with 
slightly modification (Weingarden et al. 2014). Fecal samples were suspended in 1 ml of 
50% acetonitrile (wt/vol) and extracted by vortexing and sonication for 10 min. The 
suspension was extracted twice by collecting supernatant after centrifuge at at 18,000 × g 
for 10 min, and after passage of the supernatant through a 2-µm filter, the filtrate was 
transferred to a HPLC vial and subjected to LC-MS analysis. A 5 μl of aliquot prepared 
from fecal extract was injected into an Acquity ultra-performance liquid chromatography 
(UPLC) system (Waters, Milford, MA) and separated in a BEH C18 column (Waters). The 
mobile phase was used a gradient ranging from water to 95% aqueous ACN containing 0.1% 
formic acid over a 10 min run. LC eluant was introduced into a Xevo-G2-S quadrupole 
time-of-flight mass spectrometer (QTOFMS, Waters) for accurate mass measurement and 
ion counting in negative-mode. Capillary voltage and cone voltage for electrospray 
ionization was maintained at -3 kV and -35 V for negative-mode detection. Source 
temperature and desolvation temperature were set at 120°C and 350°C, respectively. 
Nitrogen was used as both cone gas (50 L/h) and desolvation gas (600 L/h), and argon as 
collision gas. For accurate mass measurement, the mass spectrometer was calibrated with 
sodium formate solution with mass-to-charge ratio (m/z) of 50-1,000 and monitored by the 
intermittent injection of the lock mass leucine enkephalin ([M-H]- = m/z 554.2615) in real 
time. Mass chromatograms and mass spectral data were acquired and processed by 
MassLynxTM software (Waters) in centroided format. Additional structural information 
was obtained tandem MS (MSMS) fragmentation with collision energies ranging from 15 
to 40 eV. The concentration of bile acids in fecal samples were determined by calculating 
the ratio between the peak area of individual bile acids and the peak area of internal 
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standard, and then fitting with a standard curve using QuanLynxTM software (Waters). 
Morphine sulfate standard was purchased from National Institute of Drug Abuse (NIDA) 
and M-3-G standard was purchased from Sigma.  
 
Cross-correlation analysis 
Cross-correlation between gut microbiome and metabolome data were performed using 
Microbiome Package, by following instruction online. Cross-correlation between 
phylogenotypes of microbiome and metabolites were Spearsman correlation. Taxa 
relative value were transformed as the base-10 logarithm of a number before correlated 
with metabolomic relative abundance value and FDR adjusted p-value (q-value). (Leo 
Lahti and Jarkko Salojarvi. (2014). Microbiome R package. URL: 
http://microbiome.github.com) 
 
Microbial Culture 
Enterococcus faecalis strain (SL11, MMH594::pREG969luxPgelE) used in this 
study was routinely grown at 37°C without shaking in M17 medium (Oxoid Ltd., United 
Kingdom) supplemented with 0.4% (vol/vol) glucose (GM17) and spectinomycin was 
added at 500 ug/ml (Leanti La Rosa et al. 2013). 
 
Statistics 
Microbiome data were FDR adjusted p-value (q-value). Q-value < 0.05 was 
considered statistically significant. P-value in UniFrac distance comparison is 
Bonferroni-corrected. The tests of significance were performed using a two-sided 
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Student's two-sample t-test. Alternative hypothesis: Group 1 mean != Group 2 mean. 
Experimental values for fecal metabolites are expressed as means ± SEM. Statistical 
analysis was performed using t-test or ANOVA followed by Tukey’s honestly significant 
difference test on significant threshold at 𝛼 = 0.05.  P <0.05 was considered statistically 
significant. 
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RESULTS 
1. Morphine treatment induces distinct changes in gut microbiome 
Morphine treatment has been shown in our laboratory to induce bacterial 
translocation on day 2 post treatment and cause bacterial dissemination both in a mouse 
model and in human patients(Meng et al. 2013; Hilburger et al. 1997; Babrowski et al. 
2012). It has been shown that microbial dysbiosis contributes to bowel dysfunction and 
susceptibility to infectious diseases(Buccigrossi, Nicastro, and Guarino 2013; Pham and 
Lawley 2014). To determine the effect of morphine treatment on gut microbiome profile, 
we analyzed gut microbiome based on Illumina sequencing of intestinal microbial 16S-
rRNA genes. Hierarchical clustering of the samples was performed through the 
unweighted pair group method with arithmetic mean (UPGMA) using the Bray-Curtis 
similarity. The cladogram and dendrogram of a hierarchical cluster analysis showed 
distinct clustering in the morphine treatment group when compared to placebo.  Housing 
animal with same treatment group in separate boxes does not result in individual 
differences (Figure 2.1). To compare microbial patterns, a principal coordinate analysis 
(PCoA) was used. A scatter plot based on an unweighted UniFrac distance matrics 
obtained from the sequences at OTU level with 97% similarity showed a distinct 
clustering of the community composition between the morphine and placebo treated 
groups. By using unweighted UniFrac distance to evaluate beta diversity (that is diversity 
between groups, comparing microbial community based on compositional structures), we 
found that morphine treatment results in a significant shift in fecal microbiome at day 3 
post treatment compared to placebo treatment (Figure 2.2).  
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2. Morphine treatment leads to temporal modulation of gut microbiome 
Opioid-induced adverse effects such as constipation are observed in patients 
less than 24 hours following morphine administration (McNicol, Midbari, and Eisenberg 
2013). At 24 hours post treatment, mice receiving morphine revealed bacterial 
translocation to mesenteric lymph node (MLN) and liver(Meng et al. 2013). To determine 
time dependent changes in microbial composition following morphine pellet 
implantation, fecal samples were collected from the same animal at time 0, 24, 48 and 72 
hours following morphine treatment and analyzed using 16S rRNA genes sequencing.  
Control animals were implanted with a placebo pellet. To determine the role of the opioid 
receptor in morphine induced effects, morphine implanted animals were also implanted 
with a Naltrexone pellet. Our time course study revealed distinct modulation of gut 
microbiome by morphine. Principal coordinates analysis of fecal samples from day 0, day 
1, day 2, and day 3 post treatments showed that the microbial profile at day 0 in all 
treatment groups were similar and there were no distinct clustering. However, as early as 
24 hours the microbiome from the morphine treatment group clustered distinctly from all 
other groups (Figure 2.3 & Figure 2.4). Naltrexone, an opioid receptor antagonist, 
antagonized morphine's induced alteration of gut microbiome (Figure 2.5 & Figure 2.6). 
Interestingly, animals treated with naltrexone alone clustered distinctly from the placebo 
group at day 3 following implantation suggesting that endogenous opioid may set a basal 
tone on the host microbial profile.  
 
3. Morphine treatment increases pathogenic function and decreases stress tolerance of 
gut microbiome 
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To further determine if morphine treatment results in functional consequence 
following gut microbiome alteration, predicted metagenomic functional analysis was 
performed using a BugBase software package which is based on the PICRUSt analysis 
and KEGG metabolic OTUs from the GreenGenes reference database. Our results show 
that morphine treatment resulted in a significant increase in pathogenic bacterial strains 
(Figure 2.7B).  Furthermore, there is a decrease in strains associated with stress tolerance 
indicating decreased resilience against perturbation to homeostasis (Figure 2.7B). These 
results implicate that healthy commensal microbiota might be less likely to outcompete 
outgrowth of pathogenic bacteria and eliminate pathogens colonization in the gut 
following morphine treatment. Less stress tolerance of the gut microbiota community 
means that the homeostasis is more “fragile” or susceptible.  
 
4. Time course of morphine-modulated gut microbiome at genus level 
Next, we performed a time course study in the phylogenetic analysis to determine 
whether certain strains changed post morphine treatment contributed to increased 
pathogenic function and decreased stress tolerance of gut microbiome. The analysis of 
OTUs on genus level shows that relative abundance of pathogenic bacteria (genus level) 
increased significantly at day 3 post morphine treatment compared to placebo treatment 
(Figure 2.8). Increased representative pathogenic bacteria include Flavobacterium, 
Enterococcus, Fusobacterium, Sutterella, Clostridium (Figure 2.8, Table 2.1). To avoid 
false positive paradox, multiple hypothesis tests and “multiple testing correction” were 
performed by using false discovery rate (FDR), Q-value (Noble 2009). The “Q-value” is 
the FDR based measure of significance which applies to multiple hypothesis tests and can 
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be calculated simultaneously (Storey 2003). The q-value is defined to be the minimum 
FDR at which the test is called significant (Q-value < 0.05). 
 
5. Identification of association between gut microbial dysbiosis and bacteria at 
species level 
In order to confirm the pathogenic strains that constitutes distinctness of gut 
microbiome alteration, we detected expression profiling of selected species specific 
16SrRNA gene in gut microbiota by using quantitative real-time PCR. The result shows 
that expansion of Enterocuccus faecalis is associated with morphine induced alteration of 
gut microbiome (Figure 2.9A). E. faecalis 16S-rRNA gene amplification was 100 times 
greater in morphine modulated gut microbiome than placebo treated gut microbiome. The 
effect of morphine on E. faecalis expansion was observed as early as day 1in morphine 
treated animals and sustained in all days tested post treatment (Figure 2.9B). The effect of 
morphine on E. faecalis abundance in the gut microbiome was antagonized by naltrexone 
treatment. This results suggest that expansion of E. faecalis can potentially act as a 
biomarker of gut dysbiosis following morphine treatment (Figure 2.9C).  
 
6. Morphine induces distinct gut metabolomic profile 
Microbial dysbiosis leading to a disruption of host-microbes homeostasis is 
not only alteration of microbial composition, but more importantly disruption of 
functional configuration of the microbiota(Sommer and Bäckhed 2013). The intestinal 
microbiota metabolizes input substrates from host, including diet and xenobiotics, into 
metabolites that can affect the host(Ursell et al. 2014). Although gut microbiome may 
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vary in different individuals, a core functional metabolic interaction with gut microbiota 
is essential for the host and alteration of the core functional microbiome is associated 
with different physiological states(Turnbaugh et al. 2009). Thus, identification of gut 
metabolomic profile is fundamental to reveal the functional changes of gut microbiome. 
To explore changes in metabolomic profile induced by morphine treatment, a time course 
study was carried out as described earlier. Fecal samples were collected from the same 
animal following treatment at day 0, 24, 48 and 72 hours and analyzed together using 
LC-MS. Gut microbiome analysis were also performed on the same fecal samples. Scores 
scatter plot of the partial least square discriminant analysis (PLS-DA) model of fecal 
samples were performed from morphine or placebo treated samples (Figure 2.10A). The 
result shows that morphine treatment induced a distinct gut a metabolomic profile when 
compared to placebo treated group. To identify metabolites contributing to separation of 
fecal samples from mice following morphine or placebo treatments, we performed a 
loading plot of principal components analysis model in which each dot represents a single 
molecular metabolite (Figure 2.10B).  
 
7. Morphine changes gut metabolomic profile gradually and shifts metabolites 
differentially 
Metabolic profiles following morphine treatment was determined in a time 
course study. Our results show that morphine treatment resulted in a gradual and 
differential shift in metabolites in a time dependent manner (Figure 2.11). To identified 
shifts of gut metabolome following morphine treatment we performed scores scatter plot 
of the partial least square discriminant analysis (PLS-DA) model and characterized the 
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metabolomics profiling of fecal samples from wild type mice (C57B6/J) with morphine 
or placebo treatment at 0, 24, 48 and 72hours following morphine treatment (Figure 
2.11A). Morphine treatment revealed distinct clustering in the metabolome profile when 
compared with placebo treatment at each time tested. In order to reveal the details of 
metabolomic changes due to morphine treatment, we identified their chemical identities 
that increased and decreased following morphine treatment at day 3 post morphine 
treatment (Figure 2.11B). The result shows that morphine changes gut metabolomic 
profile gradually and shifts metabolites differentially in fecal matters taken from mice at 
prior to and day 1, day 2, day 3 post morphine or placebo treatment. Bile acids decreased 
gradually, while phosphatidylethanolamines (PEs) and saturated fatty acids increased as a 
consequence of morphine treatment (Figure 2.11B). 
 
8. Naltrexone antagonized morphine induced gut metabolomic shift and reversed effect 
of morphine on bile acid metabolism 
We used an opioid receptor antagonist, naltrexone, to determine whether it can 
inhibit effect of morphine on gut metabolomics profile. The result shows that naltrexone 
can inhibit morphine induced gut metabolomics shift and reverse the effect of morphine 
on bile acid metabolism (Figure 2.12A). Particularly, we established that the abundance 
of secondary bile acid, deoxycholic acid significantly decreased following morphine 
treatment and morphine induced decrease was antagonized by naltrexone (Figure 2.12B). 
The abundance of phospholipid, PE, which is a major component of cell membrane, was 
increased by morphine treatment, indicating increased cell injury, and morphine induced 
increase was reversed by naltrexone treatment (Figure 2.12B). This result indicate that 
50 
 
deoxycholic acid (DCA) levels and phosphatidylethanolamines (PE) can be used as 
biomarkers to indicate morphine-modulation of gut metabolome. 
 
9. Morphine induced dysbiosis disrupts morphine metabolism and its enterohepatic 
recirculation 
Morphine is conjugated to morphine-3-glucuronide (M3G) and morphine-3-
glucuronide (M6G) in liver and excreted to gut via biliary tract. M3G is totally inactive, 
whereas M6G appears to display stronger analgesic activity than morphine(Lötsch and 
Geisslinger 2001). Intestinal de-conjugating bacteria transform M3G and M6G to 
morphine, which is reabsorbed back to systemic circulation. The enterohepatic circulation 
plays an important role in morphine elimination, which is characterized by a prolonged 
terminal elimination phase(Ouellet and Pollack 1995). In mice and rats, M6G formation 
is insignificant, so morphine is recycled significantly via M3G. We found that the ratio of 
M3G/MS serum concentration increases between day 1 and day 6 post-treatment (Figure 
2.13) and also increases in feces between day 1 and day 2 post morphine treatment, 
indicating decreased M3G deconjugation to morphine in the gut (Figure 2.14). 
 
10. Cross-correlation of morphine-modulated gut microbiome and metabolome 
In order to further clarify if morphine-modulated gut microbiome alteration is 
associated with gut metabolomic changes following morphine treatment, we performed 
cross-correlation between gut microbiome and metabolome (Figure 2.15). The cross-
correlation shows that cholic acids, and Octadecanedioic acid are negatively associated 
with Enterococcus and Erysipelotrichaceae at the family level. While 
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phosphatidylethanolamines (PE) are negatively associated with bacteroidales (Order 
level), and positively associated with Erysipelotrichaceae. Although the cross-correlation 
analysis is only statistical evidence, however statistical inference can help reveal the 
inherent causal relationship between gut microbiome and metabolome.  
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DISCUSSION 
In this longitudinal study, we show that morphine treatment, when compared to 
placebo, induces a significant shift in gut microbiome and increased potential pathogenic 
bacteria. Phylogenetic analysis revealed that morphine treatment results in decreased 
alpha diversity and distinct clustering in a beta diversity plot when compared to placebo. 
Previous studies in our laboratory and other research groups have demonstrated that 
morphine induced increase risk in virulent bacterial infection, bacterial translocation and 
lethal gut-derived sepsis(Babrowski et al. 2012; J. Wang et al. 2005; Degenhardt et al. 
2011,Meng et al. 2015).  Our current results indicate that the increased abundance of 
potential pathogenic bacteria following morphine treatment may account for morphine 
induced bacterial translocation and sepsis.  
Richness of microbial diversity is an indicator of microbial homeostasis and less 
microbial diversity is associated with microbial dysbiosis(Bäckhed et al. 2012). Morphine 
treatment is associated with a significant decrease in gut microbial alpha diversity, 
indicating microbial dysbiosis and higher risk for dysbiosis (Figure 2.15).  
In this study, we reveal that E. faecalis is associated with morphine-modulated gut 
microbiome alteration in a time-course study. This result is alignment with serotyped 
species in our previous study on morphine-induced bacterial translocation and confirmed 
a significant prevalence of Enterococcus in all mesenteric lymph nodes (mLN), spleen, 
and liver isolates from morphine-treated animals(Meng et al. 2015). E. faecalis is 
associated with ulcerative colitis in human and opioid-induced sepsis in mouse 
model(Fite et al. 2013; Meng et al. 2015).This indicates that E. faecalis may act as 
biomarker of morphine induced sepsis and systemic bacterial translocation. In order to 
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investigate the role E. faecalis play in gut microbiome, we infected mouse in context of 
morphine treatment. In this E. faecalis infection experiment, we found that E. faecalis 
can decrease alpha-diversity and shifts beta-diversity of gut microbiome (Figure 2.6).    
This study revealed morphine changes gut metabolomic profile gradually and 
shifts metabolites differentially. The differential changes of gut metabolomics profile 
may reflect alteration of gut microbiome and therefore contribute to host response 
following morphine treatment. Cross-correlation between gut microbiome and 
metabolome indicate association between bacterial communities and functional 
metabolites (Figure 2.15). Cholic acid is negatively associated with Enterococcus and 
Erysipelotrichaceae, but positively associated with Bacteroidales. On the contrary, PEs 
and stearic acid are positively associated with Enterococcus and Erysipelotrichaceae, but 
negatively associated with Bacteroidales. Our previous study determined that morphine 
treatment leads to intestinal barrier dysfunction. It was well demonstrated that bacterial 
metabolites regulate GI barrier function via Xenobiotic Sensor PXR-dependent TLR4 
signaling pathway, suggesting alteration of gut microbiome and metabolome may 
contribute to gut barrier dysfunction following morphine treatment. Furthermore, bile 
acids can mediate host resistance to C. difficile infection. Decrease of bile acid may be 
associated with morphine-induced increase of pathogenic bacteria in gut, such as E. 
faecalis. The gut microbiome of mice that switch to high fat diet are characterized by 
Erysipelotrichaceae increase, and are associated with higher risk of infectious disease 
and inflammation(Greiner and Bäckhed 2011; Honda and Littman 2012). Taken together, 
the present study has elucidated the mechanism under which how morphine treatment 
results in pathological effects.   
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It has been well demonstrated that gut metabolites play an important link between 
gut microbes and host biological functions. Morphine treatment results in dramatic 
changes in the fecal metabolome, alters fatty acid and bile acid metabolism, and increases 
PEs levels in gut. PEs are the main lipid components of the inner bacterial membrane. An 
increase of PEs level is indicative of significant cell injury. PEs are associated with 
bacterial stress responses(R. Keller et al. 2015). In this study, analysis using BugBase 
software package suggested morphine treatment results in a decrease in stress tolerance. 
The increase of PEs in gut is associated with decreased stress tolerance.  
Morphine metabolism and elimination plays an important role in determining 
drug pharmacokinetics and assessing their efficacy and adverse effects in clinical terms. 
To investigate whether gut microbiome alteration impacts morphine metabolism is of 
essence in clinical terms. We found that the ratio of M3G/MS serum concentration 
increases between day 1 and day 6 post-treatment (Figure 2.13) and also increases in 
feces between day 1 and day 2 post morphine treatment, indicating decreased M3G 
deconjugation in gut(Figure 2.14). The major glucuronide deconjugating bacteria are the 
strict anaerobes, bacteroides, and bifidobacteria, which express the β-glucuronidase 
activity(Stain-Texier, Sandouk, and Scherrmann 1998). In present study, we show that 
morphine treatment results in a decrease in Bacteroidales, suggesting that decrease M3G-
deconjugation is a consequence of a decrease in deconjugating bacteria (Table 2.1). Our 
cross-correlation analysis results revealed that these Bacteroidales are positively 
associated with cholic acid and octadecenoic acids, but negatively associated with PEs, 
glucosides, and stearic acid, which is consistent with what we observed in morphine-
induced alteration of metabolomic profile (Figure 2.11 & Figure 2.13).  The 
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phosphatidylethanolamine-binding protein (PEBP)/(alternatively named Raf-1 kinase 
inhibitor protein or RKIP) , initially found to bind PEs has been shown to be associated 
with morphine derivatives(Atmanene et al. 2009). PEBP acts as a molecular shield and 
prevents morphine-3-glucuronide from rapid clearance(Goumon et al. 2006). These 
results revealed that loss of deconjugating bacteria, decreased bile acids and increased 
PEs in gut modulate morphine metabolism and elimination, which consequently affects 
clinical use of opioids in pain management. 
For the first time, we show emergence of distinctness in bacterial profile in the 
gut microbiome and metabolome following morphine treatment. The present study 
revealed that morphine-induced gut microbiome and metabolome shifts are inhibited by 
naltrexone, an opiate receptor antagonist, indicating morphine induced changes are opiate 
receptor dependent. Peripheral opiate receptor antagonists, such as naltrexone, can be 
exploited as potential therapeutic approach to inhibit or rescue morphine-modulation of 
gut microbiome and metabolome. We identified E. faecalis as being associated with 
intestinal microbiome in response to morphine treatment, indicating potential application 
in therapeutics and non-invasive diagnostics. In this study, we investigated various 
effects of the intestinal microbiota on the biotransformation of opioids and other small 
molecular metabolites. By understanding and altering the intestinal microbiota one may 
be able to detect and minimize the adverse effects of xenobiotics. Thus one can consider 
the intestinal microbiota as another drug target. We also identified DCA and PEs as 
molecular metabolites that represent morphine-induced alteration of gut metabolome, 
indicating potential target of therapeutic intervention. This study shed light on the 
mechanism that morphine modulates gut homeostasis provides novel approaches to avoid 
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morphine adverse side effects. Furthermore, this study may help improve medical 
intervention concerning consequences of drug use/abuse and will provide potential 
therapeutic and diagnostic strategies for opioids-modulated intestinal infections as well. 
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Figure 2.1 Morphine induced distinct clustering and distribution of gut microbiome. 
Housing animal in separate boxes does not result in individual differences. Fecal 
samples were collected from mice at day 3 post treatments. (A) The dendrogram of a 
hierarchical cluster analysis shows distinct clustering of morphine treated samples 
when compared to placebo. Hierarchical clustering of the samples with the unweighted 
pair group method with arithmetic mean (UPGMA) using the Bray-Curtis similarity 
additionally confirmed that samples from morphine treated mice clustered differently 
than those from controls. (B) The jackknifed tree with internal nodes shows the 
relationship among samples and reveals that samples from morphine treated mice 
clustering differently from that of placebo. The length of bar value explains how 
frequently a given internal node had the same set of descendant samples in the 
jackknifed UPGMA clusters as it does in the UPGMA cluster using the full data set. 
Annotation of sample names: For example, in the sample “1.72h.pl2”, the number “1” 
prior to the first dot refers to animal box number; “72h” refers to 72 hours post 
treatment; “pl2” refers to the number 2 mouse in the box 1 that placebo treatment;  
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Figure 2.2 Beta diversity measures of gut microbiome following morphine or placebo 
treatment. Wild type mice were implanted with placebo, 25mg morphine pellets 
subcutaneously. Fecal matter were taken for analysis at day 3 post treatment. (A) 
Principal coordinates analysis (PCoA) of samples using the UniFrac metric at the OTU 
level. (B) UniFrac distance significant tests were performed using QIIME. The tests of 
significance were performed using a two-sided Student's two-sample t-test. 
*Parametric p-value (Bonferroni-corrected) <0.05, ** Parametric p-value (Bonferroni-
corrected) <0.01. 
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Figure 2.3 Beta diversity measures of gut microbiome following placebo or morphine 
treatment. Wild type mice were implanted with placebo, 25mg morphine pellets 
subcutaneously. Fecal matter were taken for analysis at pre-treatment, day 1, day 2, day 
3 post treatment, respectively. Principal coordinates analysis of samples from pre-
treatment (A), day 1 (C), day 2 (E) and day 3 (G) using the UniFrac metric at the OTU 
level. The tests of significance were performed using a two-sided Student's two-sample 
t-test. *Parametric p-value (Bonferroni-corrected) <0.05, ** Parametric p-value 
(Bonferroni-corrected) <0.01. 
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Figure 2.4 Beta diversity measures of gut microbiome following placebo or morphine 
treatment. Fecal samples from day 0, day 1, day 2 and day 3 post treatments collectively 
presented on the same PCoA plot in 3D (A) or 2D (B) visualization respectively.
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Figure 2.5 Beta diversity measures of gut microbiome following placebo, morphine, 
naltrexone, or morphine plus naltrexone treatment. Wild type mice were implanted with 
placebo, 25mg morphine, 30mg naltrexone, or morphine and naltrexone pellets 
subcutaneously. Fecal matter were taken for analysis at pre-treatment, day 1, day 2, day 3 
post treatment, respectively. Principal coordinates analysis of samples from pre-treatment 
(A), day 1 (C), day 2 (E) and day 3 (G) using the UniFrac metric at the OTU level. The 
tests of significance were performed using a two-sided Student's two-sample t-test. 
*Parametric p-value (Bonferroni-corrected) <0.05, ** Parametric p-value (Bonferroni-
corrected) <0.01.  
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Figure 2.6 Beta diversity measures of gut microbiome following placebo, morphine, 
naltrexone, or morphine plus naltrexone treatment. Fecal samples from day 0, day 1, day 
2 and day 3 post treatments collectively presented on the same PCoA plot in 3D (A) or 
2D (B) visualization respectively. 
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Figure 2.7 Microbiome based functional phenotype analysis. Morphine treatment results 
in a significant increase of pathogenic bacteria (A) and decrease of stress tolerance (B). 
Predicted metagenomic functional analysis were performed by using BugBase software 
package, which is based on the PICRUSt analysis and KEGG metabolic OTUs from the 
GreenGenes reference database. (A) FDR-corrected p-value is: 0.004662005; (B) FDR-
corrected p-value is: 0.0001554002. 
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Figure 2.8 Morphine treatment results in a significant increase of pathogenic bacteria. 
Multiple hypothesis test with the given threshold (FDR=0.05) shows relative 
abundance of pathogenic bacteria (genus level) increase significantly at day 3 post-
treatment with morphine treatment compared to placebo treatment. Increased (red 
color) representative pathogenic bacteria include Flavobacterium, Enterococcus, 
Fusobacterium, Sutterella, Clostridium. 
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Table 2.1 Taxonomic significance test in gut microbiome following morphine or placebo 
treatments. Taxa features were selected by their ranked individual hypothesis test p-
values and false discovery rate, q-value. The statistical analysis were performed by using 
MWAS R Package v0.9.3.  
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Figure 2.9 Enterocuccus faecalis is biomarker of morphine induced alteration of gut 
microbiome. Real-time PCR expression profiling of species specific 16S-rRNA gene in 
gut microbiota. (A) The expression of species specific 16S-rRNA gene was profiled in 
stool samples from eight mice s.c. implanted with placebo (control) and eight with 
morphine (treatment) using a qRT-PCR assay. The heatmap was generated by the real-
time PCR data presented as ΔCT (CT_species – CT_universal_16SrRNA). A greener 
color indicates higher level of amplification. (B) E. Faecalis 16S-rRNA gene 
amplification fold change due to treatments on day 3 post treatment. (C) E. Faecalis 16S 
rRNA genes amplification fold change due to treatments in a longitudinal study. 
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Figure 2.10 Metabolomic analysis of fecal matter and identification of metabolites 
changes. Mice were treated with 25mg morphine or placebo pellet subcutaneously. 
Fecal matter were taken for analysis at 3 days post treatment. (A) Scores scatter plot of 
the partial least square discriminant analysis (PLS-DA) model of fecal samples from 
wild type mice (C57B6/J) with morphine (□) or placebo (Δ) treatment. The t[1] and 
t[2] values represent scores of each sample in principal components 1 and 2, 
respectively. (B) Loadings plot of principal components analysis model. Metabolites 
contributing to separation of fecal samples from mice following morphine and placebo 
treatment were labeled, and their chemical identities are confirmed. 
 
  
68 
 
  
Figure 2.11 Metabolomic analysis of fecal matter and identification of significant 
shifts of gut metabolome following morphine treatment. In a longitudinal study, fecal 
matters were taken from mice at prior to and day 1, day 2, day 3 post morphine or 
placebo treatment. (A) Scores scatter plot of the partial least square discriminant 
analysis (PLS-DA) model of fecal samples from wild type mice (C57B6/J) with 
morphine (□) or placebo (Δ) treatment. The t[1] and t[2] values represent scores of 
each sample in principal components 1 and 2, respectively. (B) Heatmap plot of 
significant associations with morphine treatments and the loading of indicator 
metabolites in fecal matter from mice. All relative abundances are row z-score 
normalized for visualization. 
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Figure 2.12 Metabolomic analysis of fecal samples and measurement of effects of 
naltrexone on morphine induced gut metabolomic shifts. Mice were treated with 
placebo, 25mg morphine, 30mg naltrexone, or morphine + naltrexone pellets 
subcutaneously. Fecal matter were taken for analysis at 3 days post treatment. (A) 
Scores scatter plot of the partial least square discriminant analysis (PLS-DA) model of 
fecal samples from wild type mice (C57B6/J) with morphine (□) or placebo (Δ) 
treatment. The t[1] and t[2] values represent scores of each sample in principal 
components 1 and 2, respectively. (B) Relative abundance analysis of metabolites 
reveals reversed naltrexone, an opioid receptor antagonist, reversed the effect of 
morphine on loading of deoxycholic acid (DCA), a secondary bile acid, and 
phosphatidylethanolamines (PEs), a class of phospholipids found in biological 
membranes. 
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Figure 2.13 The ratio of M3G/MS serum concentration increases post morphine 
treatment. LC-MS analysis identified MS and M3G concentration in mouse serum. 
Statistical significance tests were performed using Student t test. P<0.05.  
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Figure 2.14 The ratio of M3G/MS fecal concentration increases post morphine treatment. 
LC-MS analysis identified MS and M3G concentration in mouse feces. Statistical 
significance tests were performed using Student t test. P<0.05.  
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Figure 2.15 Cross-correlation analysis between gut microbiome and metabolome. Cross-
correlation between phylogenotypes of microbiome and metabolites were Spearsman 
correlation. Taxa relative value were transformed as the base-10 logarithm of a number 
before correlated with metabolomic relative abundance value and FDR adjusted p-value 
(q-value). Significance was considered as q-value < 0.05.   
 
  
73 
 
 
 
Figure 2.15 Alpha diversity in gut microbiome following morphine or placebo 
treatment. (A) Alpha diversity were assessed by using chao1 index. Morphine 
treatment (n=8) results in decreased alpha diversity compared to controls (n=8) 
measured by using chao1 index. The OTU table were rarefied at the cutoff value of 
31000 sequences per sample. (B) t-test was conducted on chao1 index. ** indicates 
significantly different, P value=0.0030. 
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Figure 2.16 E. faecalis infection alters gut microbiome following morphine treatment. 
(A) Morphine decrease alpha diversity in context of E. faecalis infection. (B) Significant 
analysis of Alpha diversity (Chao1 index) by using two-way ANOVA. Interaction 
between morphine treatment and E. faecalis infection accounts for 1.62% of the total 
variance. The P value =0.3616. The interaction is considered not significant. Morphine 
treatment accounts for 8.44% of the total variance. The P value = 0.0434. The effect is 
considered significant. E. faecalis infection accounts for 37.09% of the total variance. 
The effect is considered extremely significant. (C) Morphine induced distinct gut 
microbiome clustering in context of E. faecalis infection. (D) Significant analysis showed 
measures of beta diversity using UniFrac distance metrics. E. faecalis infection 
dominated the alteration of gut microbiome and leads to a less different beta diversity 
clustering when compared to samples without E. faecalis infection.     
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Figure 2.17 Model of metabolism and biotransformation of morphine and bile acids. In 
liver, cholesterol were transformed to primary bile acids, and morphine were 
conjugated to M3G.  In gut, intestinal bacteria transform primary bile acids and M3G 
into secondary bile acids and morphine respectively. Bile acids and morphine are 
reabsorbed and recycled via enterohepatic circulation.  
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CHAPTER 3 
MORPHINE TREATMENT POTENTIATES 
CITROBACTER RODENTIUM VIRULENCE, SYSTEMIC 
DISSEMINATION AND EXACERBATES GUT DYSBIOSIS 
 
INTRODUCTION 
Risk of lethal bacterial infection is a tremendous concern for hospitalized 
patients(Fagundes-Neto and de Andrade 1999; Larney et al. 2015). Opioids induce 
immunosuppression and bowel dysfunction leading to increased susceptibility to bacterial 
and opportunistic infections(Mora et al. 2012). Chronic morphine has also shown to 
lower host defense to enteric bacteria such as Salmonella enterica and Pseudomonas 
aeruginosa(Feng et al. 2006; Babrowski et al. 2012), induce spontaneous sepsis in 
mice(Hilburger et al. 1997), increase mortality following Acinetobacter baumannii 
infection or lipopolysaccharide (LPS) treatment in mice(Breslow et al. 2011).We have 
recently shown that morphine induced bacterial translocation in mice by compromising 
intestinal barrier function(Meng et al. 2013). The aim of the studies is to investigate if 
opioids use increase virulence and susceptibility to a common hospital acquired infection. 
The interaction between gut microbiota and intestinal epithelial surface play 
important roles in preventing the outgrowth of pathogenic organisms and maintaining 
gastrointestinal homeostasis(Marchiando, Graham, and Turner 2010; Wells et al. 2011). 
The disruption of commensal gut microbiota contributes to pathogenic bacteria 
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colonization in gut(Blaschitz and Raffatellu 2010; Balzan et al. 2007). Other than 
composition of bacterial species in gut microbiota, bacterial virulence is 
pathophysiologically important in intestinal bacterial infection. In the early stage of 
intestinal infection, bacterial virulence genes are expressed and required for pathogen 
growth on the gut epithelium surface(Kamada, Chen, and Núñez 2012). Pathogen 
bacterial colonization and invasion are always accompanied by collapse of host 
homeostasis by dysregulating immune response, disrupting gut barrier function and 
disturbing commensal microbiome. Enteropathogenic E. coli (EPEC) and 
Enterohemorrhagic E. coli (EHEC) are important causes of diarrheal disease and are 
human specific(Bergstrom et al. 2010). C. rodentium is a natural mouse pathogen that 
models intestinal infection by enteropathogenic Escherichia coli (EPEC) and 
enterohemorrhagic E. coli (EHEC) in humans and causes attaching and effacing (A/E) 
lesions and colonic hyperplasia in human and animal hosts leading to diarrhea (Luperchio 
et al. 2000). To facilitate colonization and invasion, C. rodentium delivers virulence 
factors, such as translocated intimin receptor (Tir) and virulence genes regulator, Ler 
protein. C. rodentium colonization depends on virulence factor-mediated adhesion and 
provoke inflammation, which further disrupts gut microbiota and promotes the outgrowth 
of pathogenic bacteria (Lupp et al. 2007). Regulation of the virulence factor-mediated 
colonization and commensal-driven pathogen eradication may be potential therapeutic 
strategies. However, it is unclear whether and how morphine modulates 
pathophysiologically important functional changes in bacterial virulence.  
Here, by using a mouse-model of C. rodentium infection, we determined effects 
of morphine on gut homeostasis and host resistance against C. rodentium infection.  
78 
 
MATERIALS AND METHODS 
Mice 
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). 
All animals were maintained in pathogen-free facilities and all procedures were approved 
by the University of Minnesota Institutional Animal Care and Use Committee. 8–10 
week old animals were used for our studies. All surgery was performed under isoflurane 
anesthesia, and all efforts were made to minimize suffering. 
 
Bacterial strains  
C. rodentium strain (DBS 100) was obtained from American Type Culture 
Collection (ATCC; Manassas, VA). Nalidixic acid resistant C. rodentium was selectively 
screened out on LB agar plate with 20ug/ml Nalidixic acid. A spontaneous mutant of C. 
rodentium DBS100 resistant to nalidixic acid (20μg/ml) would be obtained by growing 
DBS100 at 37°C in LB medium supplemented with nalidixic acid at 5μg/ml for 7 h 
before spreading the liquid culture onto LB agar plates supplemented with nalidixic acid 
at 20μg/ml. The selective LB agar plates and broth would be made by adding nalidixic 
acid up to 20μg/ml in order to selectively culture C. rodentium in the future study 
(Gueguen and Cascales 2012). The nalidixic acid solution was made with Mili-Q water in 
fume hood and the stock solution was sterilized through a 0.22um filter using a 10-ml 
syringe with in the sterile hood. Kanamycin resistant C. rodentium was obtained from Dr. 
Bruce A. Vallance laboratory at University of British Columbia, Vancouver, Canada 
(Bhinder et al. 2013). Bioluminescent strains of C. rodentium were constructed by 
introducing plasmid pT7 carrying the entire lux operon from Photorhabdus luminescens. 
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For selective culture of C. rodentium, kanamycin (SKU 60615, Sigma) was added into 
LB broth or agar plates at the concentration of 30 ug/ml. 
 
Animal treatment and bacterial oral infection 
Mice received placebo or 25mg morphine pellet implantation as described(Bryant 
et al. 1988). Placebo or 25 mg morphine pellets (National Institutes of Health 
[NIH]/National Institute on Drug Abuse [NIDA], Bethesda, MD) were inserted in a small 
pocket created by a small skin incision on the animal’s dorsal side; incisions were closed 
using surgical wound clips (Stoelting, 9 mm Stainless Steel, Wooddale, IL). Mice were 
subcutaneously treated with placebo or 25mg morphine pellet for 24hr prior to infection. 
Mice were infected with 1x109 C. rodentium in 200ul medium via oral gavage(Bhinder et 
al. 2013). Mice were sacrificed for study at day 5 post infection with C. rodentium. 
 
Colony forming Units   
Bacterial culture on blood agar plates without antibiotics or LB agar plates with 
20ug/ml Nalidixic acid or 30ug/ml Kanamycin over night at 37oC.  
 
Histology of animal tissues 
Animal intestinal tissues were collected at appropriate time points, fixed in 10% 
buffered formalin and embedded in paraffin. Paraffin specimens were cut into 5µm 
sections and mounted on microslides. Hematoxylin and eosin (H&E) and Alcian blue 
staining were performed on paraffin embedded sections, and stained slides were reviewed 
using Leica DM5500B Microscope. 
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Fluorescence in situ hybridization (FISH).  
Detection of commensal bacteria: Use Alexa-Fluor 488 (FITC)-labeled Eub338 
(5’-GCT GCC TCC CGT AGG AGT-3’), which is a universal probe complementary to 
the 16s RNA of virtually all bacteria were performed to determine the infiltration of 
bacteria into the colonic epithelium. This allows direct visualization of bacteria within the 
colonic mucosa. Blue color indicates nucleus staining with DAPI; green color indicates 
bacteria staining with FITC.  
Detection of C. rodentium: Paraffin-embedded sections were deparaffinized and 
rehydrated as described above. Sections were incubated overnight at 37°C in the dark 
with Texas red-conjugated EUB338 general bacterial probe (5’-GCT GCC TCC CGT 
AGG AGT-3’) and an AlexaFluor 488 conjugated GAM42a probe (5’-GCC TTC CCA 
CAT CGT TT-3’) that recognizes bacteria that belong to the γ-Proteobacter class diluted 
to a final concentration of 2.5 ng/μl each in hybridization solution (0.9 M NaCl, 0.1 M 
Tris pH 7.2, 30% Formamide, 0.1% SDS). Sections were then washed once in the dark 
with hybridization solution for 15 minutes with gentle shaking. This step was repeated 
once with wash buffer (0.9 M NaCL, 0.1 M TRIS pH 7.2), and sections were placed in 
dH2O, and then mounted using ProLong Gold Antifadereagent with DAPI (Molecular 
Probes) and imaged using Leica DM5500B Microscope. 
 
mRNA expression primers   
Ler F 5’-AAT ATA CCT GAT GGT GCT CTT G-3’ ; R 5’-TTC TTC CAT TCA 
ATA ATG CTT CTT-3’; Tir  F 5’-TAC ACA TTC GGT TAT TCA GCA G-3’; R 5’-
GAC ATC CAA CCT TCA GCA TA-3’. rrsA (16SRNA); 5’-AGG CCT TCG GGT TGT 
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AAA GT-3’ and 5’-ATT CCG ATT AAC GCT TGC AC-3’. Quantitative real-time 
polymerase chain reaction (PCR) was performed on an Applied Biosystems 7500 
Realtime PCR Detection system. All samples were run in triplicate, and relative mRNA 
expression levels were determined after normalizing all values to 16S rRNA. 
 
Flow cytometric analysis 
Cells from mesenteric lymph nodes (mLNs) were isolated and fixed for flow 
cytometry. CD4+, CD17A+ and CD17F+ were stained for analysis. 
 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software version 5.0 
(GraphPad Software Inc.). Differences between two groups were evaluated using 
Student’s t test (parametric) or Mann-Whitney U test (non-parametric). For the multiple 
comparisons, statistical analysis was performed using one-way ANOVA (parametric) or 
Kruscal-Wallis test (non-parametric), and Bonferroni test for parametric samples. 
Differences at P<0.05 were considered significant. 
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RESULTS 
1. Morphine treatment increases C. rodentium systemic dissemination 
High risk of bacterial infection in hospitalized patients is a significant concern 
especially in those patients that are on opioids for pain management. (Sabita Roy et al. 
2011; Larney et al. 2015). To determine whether morphine treatment can increase 
dissemination of C. rodentium following infection, we infected mice with C. rodentium at 
day 1 post morphine treatment mimicking bacterial infections in opioids users. C57/BL6J 
wild type mice were implanted with 25mg morphine or placebo pellet subcutaneously. 
Mice were infected with 200ul (~10^9) C. rodentium through oral gavage right after 
morphine treatment. Mesenteric lymph nodes (MLNs), spleen and liver were collected 
and homogenized in 1 ml, 2 ml and 5 ml PBS respectively at day 5 post infection. 100ul 
suspensions and 100 ul collected blood were cultured on LB agar plates with 50ug/ml 
Nalidixic acid over night at 37oC. The colony forming units (CFUs) were counted. At day 
5 post C. rodentium infection, placebo-implanted mice showed very few colonies 
growing on the antibiotic selective LB agar plates, indicating no systemic dissemination. 
However, mice receiving morphine revealed an increased number of CFUs, indicating 
systemic dissemination of C. rodentium into mesenteric lymph nodes, spleen, liver and 
blood circulation (Figure 3.1).  
 
2. Morphine treatment facilitates bacterial adherence 
The first stage of intestinal bacterial infection requires bacterial adherence to the 
gut epithelial surface(Baumgart et al. 2007; H. M. Martin et al. 2004). To determine 
whether bacterial adherence to intestines were increased by morphine treatment, we 
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determined commensal bacterial adherence to intestines following morphine treatment. 
C57/BL6J wild type mice were implanted with 25mg morphine or placebo pellet 
subcutaneously. After 24 hours, duodenum, jejunum, ileum, and colon were collected and 
washed, then homogenized with 5ml PBS. 100 ul tissue suspensions were cultured on 
blood agar plates over night at 37oC. Bacterial colonies were quantified and described as 
colony forming units (CFUs). Compared with placebo treatment, morphine increased 
commensal bacterial adherence to jejunum, ileum and colon, but not to duodenum 
(Figure 3.2A). To visualize the bacterial adherence to intestinal epithelium, we 
determined bacterial adherence through fluorescence in situ hybridization (FISH) on 
frozen tissue sections by using FITC-labeled universal probe EUB-388. Small intestine 
were excised and processed to 5um thickness cryostat sections for FISH staining. Blue 
color indicates nucleus staining with DAPI and green color indicates bacteria staining 
with FITC (Figure 3.2B&C). The FISH results revealed morphine treatment increased 
bacterial adherence to small intestine and disrupted histological structure of mucosal 
surface of small intestine. 
Furthermore, to determine C. rodentium bacterial adherence to intestines, we 
conducted FISH on tissue sections and visualized the g-Proteobacteria class to which C. 
rodentium belongs by using GAM42a probe. The FISH results revealed morphine 
treatment increased C. rodentium adherence to small intestines and colon, when 
compared to placebo treatment (Figure 3.3). 
 
3. Morphine treatment increases C. rodentium virulence 
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Pathogen colonization in the intestine has been shown to be controlled by 
bacterial virulence and through competition with gut commensal microbiota(Kamada et 
al. 2012; Kamada, Seo, et al. 2013). To investigate if morphine treatment increases C. 
rodentium virulence, we determined virulence factors, ler and tir, mRNA levels by 
quantitative polymerase chain reaction in fecal pellets of mice infected with C. rodentium 
at day 5 post infection. Expression was normalized to that of the 16S rRNA genes. 
Expression of virulence factors, Ler and Tir, were significantly increased in the morphine 
treatment group when compared to placebo. Same effects were seen in fecal samples of 
small intestines, cecum and colon (Figure 3.4).    
 
4. Morphine increases C. rodentium load in fecal matter and shifts gut microbiome.  
Expression of ler and tir is essential for pathogen colonization in the intestines of 
mice, we next asked the question whether morphine can increase C. rodentium growth in 
intestine contents and modulate gut microbiome in the context of C. rodentium infection. 
To determine the C. rodentium load, we collected fecal matters and homogenized in PBS 
at day 5 post infection. 100 ul suspensions were cultured on LB agar plates with 
kanamycin over night at 37 oC. Colony forming units (CFUs) were quantitated. Results 
revealed that morphine treatment increases C. rodentium growth in intestinal contents 
(Figure 3.5). Fecal bacterial DNA were isolated and purified for microbiome analysis. 
Alpha diversity analysis results revealed, when compared to placebo, C. rodentium 
infection decreases alpha diversity of the gut microbiome. However, morphine treatment 
did not further decrease alpha diversity of gut microbiome in the context of 
infection(Figure 3.6A). Beta diversity analysis results revealed morphine treatment shifts 
85 
 
gut microbiome in the context of C. rodentium infection, indicating that the relative 
bacterial abundance and composition were changed (Figure 3.6B).      
 
5. Morphine treatment disrupts integrity of epithelial barrier function in the context of 
C. rodentium infection 
The gut has a large surface area (400 sq m), which is necessary to absorb 
nutrients, and the gut epithelial barrier contains only a single layer of 
epithelium(Lozupone et al. 2012). Thus, intestinal immune defense is designed to allow 
immune surveillance of pathogens, while it operates with minimal disruption to the 
absorptive function of the gut(Hooper, Littman, and Macpherson 2012). To begin to 
understand early events that occur in morphine-treated mice that can precipitate increased 
C. rodentium infection, we evaluated the extent of inflammation and epithelial damage at 
day 5 post infection. Histologic evaluation of the extent of epithelial damage revealed 
that morphine treatment disrupts morphological structure of mucosal surface of intestines 
(Figure 3.7 & 3.8). Histological evaluation of the tight junction protein ZO-1 on sections 
of jelly-rolled small intestines and colons revealed morphine treatment decreased tight-
junction organization between intestinal epithelial cells (Figure 3.9). However, C. 
rodentium infection alone does not result in histological damages in intestinal mucosal 
epithelial integrity and barrier function.  
  
6. Morphine treatment inhibits C. rodentium-induced increase of goblet cells. 
Goblet cells secrete mucus to protect the lining of the intestine. To determine 
whether morphine modulate expression of goblet cells in the mucosal lining of the small 
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intestine and colon, we evaluated goblet cells on intestinal sections by using Alcian 
staining on jelly-rolled intestinal sections. In each section, goblet cells were counted on 
20 microvilli on epithelial surface of small and large intestines. Following Alcian blue 
staining, intensely blue material, interpreted as mucus, is evident within the goblet cells 
lining the intestinal epithelium. Faint blue material (mucus) is also present within the 
adjacent intestinal lumen. Alcian staining results revealed that morphine treatment can 
inhibit C. rodentium induced increase in the number of goblet cells in small intestines and 
large intestines, although morphine alone does not decrease the number of goblet cells 
when compared to placebo (Figure 3.10 & 3.11).  
7. Morphine treatment disrupts C. rodentium induced IL17a immune response 
At early phase of infection, C. rodentium induces an IL-17 dependent bacterial 
clearance in wild type mice (Geddes et al. 2011). To determine whether morphine 
treatment modulates C. rodentium induced IL17 immune response in mice, we 
determined the IL17 immune response by flow cytometry. Cells from mesenteric lymph 
nodes (mLNs) were isolated and fixed for flow cytometry. CD4+, CD17A+ and CD17F+ 
were stained for analysis. The flow cytometry results revealed that morphine treatment 
disrupts C. rodentium induced IL-17A immune response at day 5 post infection (Figure 
3.12 A, C, D). Morphine treatment also decreased the percentage of CD4+ cells in 
mesenteric lymph nodes in the context of C. rodentium infection (Figure 3.12C). Neither 
morphine treatment nor C. rodentium infection regulated IL-17F immune response 
(Figure 3.12B).   
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DISCUSSION 
Opioid users and abusers are at a higher risk for infectious diseases (Mora et al. 
2012; Sabita Roy et al. 2011). Animals treated with morphine exhibit greater 
susceptibility to enteric infections with strains, such as Salmonella enterica, Listeria 
monocytogenes, Vibrio cholerae, and Pseudomonas aeruginosa(Asakura et al. 2006; 
Cray, Tokunaga, and Pierce 1983; Babrowski et al. 2012; MacFarlane et al. 2000). To 
date, opioid analgesics are the most commonly prescribed medications for pain 
management. As such, the correlation between opioids usage and increased susceptibility 
to pathogenic strains need to be well investigated. When orally inoculated into wild type 
mice, C. rodentium can’t colonize in their hosts and cause pathology(Kamada et al. 
2012). In wild type mice, commensal gut microbiota can outcompete invading C. 
rodentium and inhibit their colonization in host. Intact intestinal barrier function and host 
immune response to pathogens may also contribute to eradication of C. rodentium from 
wild type mice. In present study, for the first time, we demonstrate that morphine 
increases C. rodentium virulence and potentiates systemic dissemination in wild type 
mice. 
In this study, we utilize a C. rodentium-mouse model to determine morphine 
treatment increases, Tir and Ler, two remarkable virulence factors of C. rodentium. While 
establishing colonization, C. rodentium delivers a variety of virulence factors, such as 
translocated intimin receptor (Tir), into epithelial cells by means of the type III secretion 
system in order to facilitate their adherence and invasion(Yi and Goldberg 2009). EspFU 
directly binds and activates N-WASP, leading to actin polymerization events. The 
expression of most virulence genes in C. rodentium is controlled by a regulator, Ler 
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protein, a member of the histone-like nucleoid structuring (H-NS) protein family(Puente 
et al. 2004). Thus, Ler is a virulence factor that regulates C. rodentium virulence. It has 
been demonstrated that morphine treatment can activate the virulent factors of 
Pseudomonas and induce gut derived sepsis(Babrowski et al. 2012). Increased bacterial 
virulence may promote C. rodentium colonization in gut and results in microbial 
dysbiosis. It has been shown in our study, morphine treatment increases C. rodentium 
growth in gut and changes composition of gut microbial communities. C. rodentium 
infection and morphine treatment result in distinct gut commensal microbiome. In return, 
microbial dysbiosis enhances bacterial infections(Pham and Lawley 2014).   
The gut homeostasis is reached through normal microbes-host interactions. The 
disruption of barrier function and increased growth of pathogenic bacteria are significant 
disturbance to gut homeostasis. In normal hosts, commensal bacteria activate homeostatic 
response by host immune system that permit coexistence with potential toxic bacterial 
products through down-regulating bacterial receptors, inhibiting pathogenic innate and 
adaptive immune responses, inducing antimicrobial peptides, and promoting mucosal 
barrier repair(Sartor 2008). This study showed that morphine treatment increases 
bacterial attachment to intestines in wild type mice in comparison with placebo treatment, 
suggesting morphine can modulate the interaction of microbiota and intestinal surface. 
Our study shows that morphine treatment resulted in increased expression of the 
virulence factors, Ler and Tir. It has been shown morphine treatment increases 
infiltration/adherence of bacteria to the gut epithelium by using fluorescence in situ 
hybridization (FISH) on intestinal cryostat sections. However, C. rodentium infection 
alone is unable to damage tight junction protein ZO-1 and disrupt intestinal barrier 
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function. Morphine treatment disrupts epithelial barrier function and results in impaired 
morphologic mucosal structure in the context of C. rodentium infection. The histological 
evidence reveals disruption of intestinal barrier function by morphine treatment may 
contribute to systemic dissemination of C. rodentium.   
Intestinal mucus is secreted by goblet cells in the epithelial lining of mucosal 
surface,  and forms the first line of host defense against invading pathogens, prevent 
pathogen colonization and remove the adherent load from mucosal surface(Babrowski et 
al. 2012; Benjamin P Willing, Russell, and Finlay 2011). Commensal microbiota 
facilitates host barrier function through upregulation of the mucus layer(Kamada, Chen, 
et al. 2013). C. rodentium induces increased amount of goblet cells, however, morphine 
treatment decreases the amount of goblet cells in villi of mucosal epithelial surface in the 
context of C. rodentium infection, indicating mucus excreting goblet cells are attenuated. 
How morphine modulates goblet cells is still unclear. It has been shown an innate 
immune regulatory pathway, NLRP6, regulates goblet cell mucus secretion(Wlodarska et 
al. 2014). NLRP6 deficient mice are unable to clear C. rodentium from mucosal surface 
and exhibit goblet cell impairment. NLRP6 inflammasome plays an important role in 
maintaining gut commensal microbiota and regulates gut microbial ecology(Chen et al. 
2011; Elinav et al. 2011). However, how morphine treatment modulates NLRP6 pathway 
remains unknown. It is worthy to be noted that future study should be done to elucidate 
whether morphine modulate goblet cell and gut microbiome through NLRP6 pathway.  
Intestinal commensal microbiota and host immune system co-evolved for millions 
of years and developed the symbiotic relationship to achieve a balanced, mutually 
beneficial state(Chu and Mazmanian 2013). Innate barriers ensure a tolerant immune 
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response to the microbiota(Hooper, Littman, and Macpherson 2012). At early phase of 
infection (4-7 days post infection), C. rodentium induces an IL-17 response in the cecum 
and colon (Geddes et al. 2011). It was well demonstrated that robust IL-17A secretion is 
crucial for C. rodentium clearance in late stage of infection(Z. Wang et al. 2014; Geddes 
et al. 2011). Furthermore, it has become clear that rapid IL-17A-dependent innate 
immune response is necessary for maintaining gut homeostasis (Sonnenberg and Artis 
2012). Morphine treated mice with C. rodentium infection exhibited low CD4+ T cell 
counts and decreased CD4+ T cell expression of the proinflammatory cytokine IL-17A, 
compared with infected placebo group. This study demonstrates that morphine treatment 
inhibits C. rodentium-induced IL-17A immune response, thus suppressing gut mucosal 
immune protection against invading C. rodentium.  
It has been demonstrated that innate lymphoid cells (ILCs) are major IL-17/IL22 
producing immune cells and play important roles in intestinal homeostasis(Rubino, 
Geddes, and Girardin 2012; Hepworth et al. 2013). However, it is unknown whether 
morphine modulate ILCs proliferation and recruitment during C. rodentium infections. 
Previous study in our laboratory shows that morphine disrupts positive signals 
interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against 
Streptococcus pneumoniae infection(Ma et al. 2010). It has been demonstrated that 
retinoic acid receptor related orphan receptor γτ positive (RORgt+) ILCs regulate 
intestinal homeostasis by integrating negative signals such as IL-25, which is independent 
of IL-23(Gladiator et al. 2013; Hepworth et al. 2013). However, it is unknown whether 
morphine modulates ILCs by regulating negative signal IL-25 expression and IL-25 
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responsive DC. Because of bidirectional relationship between gut microbiota and host 
immune system, it is difficult to determine the primary effects of morphine.  
To summarize, we report that morphine treatment in a mouse model of C. 
rodentium infection results in 1) promotion of C. rodentium systemic dissemination, 2) 
increase in virulence factors expression and C. rodentium colonization in intestinal 
contents, 3) altered gut microbiome, 4) damaged integrity of gut epithelial barrier 
function, 5) goblet cells differentiation, 6) dysregulated IL17A immune response. This is 
the first study to demonstrate that morphine promotes pathogen dissemination in the 
context of C. rodentium intestinal infection. This study demonstrates and further validates 
and establish a positive correlation between that opioid drug use/abuse, increase risk of 
infections. These results indicate morphine modulates virulence factor-mediated adhesion 
of pathogenic bacteria and induces disruption of mucosal host defense during C. 
rodentium intestinal infection in mice, suggesting over-prescription of opioids may 
increase the risk in the emergence of pathogenic strains and should be used cautiously. 
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Figure 3.1 Morphine increases systemic dissemination of C. rodentium. Wild type 
mice were infected with Kanamycin resistant C. rodentium via oral gavage. Each 
mouse were infected with 1x109 C. rodentium in 200ul. Bacterial load is determined by 
bacterial culture on LB agar plates with 30 ug/ml Kanamycin over night at 37oC. 
Bacterial colonies were quantified and described as colony forming units (CFU). N=5 
and above for the quantitative data. ** indicates p< 0.01 in comparison with the 
matching treatments. 
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Figure 3.2 Morphine increases commensal bacterial adherence to intestines. (A) 
Bacterial adherence to intestines is determined by bacterial culture on blood agar plates 
over night at 37oC. Bacterial colonies were quantified and described as colony forming 
units (CFU).   N=5 and above for the quantitative data. ** indicates p< 0.01 in 
comparison with the matching treatments. (B) and (C) Fluorescence in situ 
hybridization (FISH) determines bacterial adherence to the intestinal epithelium using 
FITC-labeled universal probe EUB-388. Wild type mice (B6/129PF1) were 
subcutaneously treated with placebo (B) or 25mg morphine (C) pellets for 24hr. Small 
intestine were excised and processed to 5um thickness cryostat sections for FISH 
staining. Blue color indicates nucleus staining with DAPI; green color indicates 
bacteria staining with FITC. Representative photomicrographs of FISH stained slides at 
10x. 
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Figure 3.3 Morphine increases C. rodentium adherence to intestines. Visually blue 
color indicates nucleus staining with DAPI, red color is all true bacteria (EUB338 
probe), and green color indicates bacteria staining with FITC, the γ-Proteobacteria 
class to which C. rodentium belongs (GAM42a probe), yellow color is merge of red 
and green. 
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Figure 3.4 Morphine increases the expression of virulence factors of C. rodentium. (A) 
ler and (B) tir mRNA levels were determined by quantitative polymerase chain 
reaction in fecal pellets of mice infected with C. rodentium at day 5 post infection. 
Data represent mRNA expression relative to that of the 16S rRNA gene. Results are 
means ± SEM of individual mice (n=4). Results are representative of at least two 
experiments. *P<0.05,  **P<-.01. 
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Figure 3.5 Morphine increases C. rodentium bacterial load in the intestinal contents at 
day 5 post infection. WT mice (n=7) were infected with 1x10^9 colony-forming units 
(CFUs) of C. rodentium, and pathogen load in feces were determined over the 
indicated time.  Mice were subcutaneously treated with placebo or 25mg morphine 
pellet for 24hr prior to infection. Data points are means ± SEM. Results are 
representative of at least two independent experiments. **P<0.01, Student t test. 
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Figure 3.6 Morphine treatment alters gut microbiome in the context of C. rodentium 
infection. (A) Alpha diversity were assessed by using chao1 index. (B) t-test was 
conducted on chao1 index. (C) Principal coordinates analysis (PCoA) of samples using 
the UniFrac metric at the OTU level. (D) UniFrac distance significant tests were 
performed using QIIME.  ** indicates significantly different, P value<0.01. 
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Figure 3.7 Morphine treatment disrupts morphological structure of mucosal surface of 
small intestine. H&E staining were performed on paraffin embedded sections of large 
intestines. 
  
99 
 
 
Figure 3.8 Morphine treatment disrupts morphological structure of mucosal surface of 
colon. H&E staining were performed on paraffin embedded sections of large intestines. 
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Figure 3.9 Morphine treatment disrupts ZO-1 tight junction organization in epithelium. 
Wild type mice were implanted with 25 mg morphine pellet subcutaneously and orally 
infected with C. rodentium. The small intestines and colons were excised and fixed. 
Images were analyzed by Leica fluorescent microscope. 
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Figure 3.10 Morphine reduces C. rodentium infection induced proliferation of goblet 
cells in small intestine. Alcian blue staining of additional sections of the small 
intestines resulted in bright blue staining of the cytoplasm of the goblet cells lining the 
intestinal epithelium. Goblet cells were evaluated by using Alcian staining on jelly-
rolled intestinal sections. In each section, goblet cells were counted on 20 microvilli on 
epithelial surface of large intestines. Significance test were performed using Student t 
test. *P≤0.05, **P≤0.01. 
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Figure 3.11 Morphine reduces C. rodentium infection induced proliferation of goblet 
cells in colon. Alcian blue staining of additional sections of the large intestines resulted 
in bright blue staining of the cytoplasm of the goblet cells lining the intestinal 
epithelium. Goblet cells were evaluated by using Alcian staining on jelly-rolled 
intestinal sections. In each section, goblet cells were counted on 20 microvilli on 
epithelial surface of large intestines. Significance test were performed using Student t 
test. *P≤0.05, **P≤0.01. 
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Figure 3.12 Morphine disrupts infection induced IL-17A immune response. Flow 
cytometry analysis of cells isolated from mesenteric lymphnodes (mLN). WT mice 
were subcutaneously treated with placebo or 25mg morphine pellet for 24hr prior to 
infection. Mice were sacrificed at day 5 post infection. (N=3 and above), P<0.05, 
student t test. 
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CONCLUSION 
Opioids are frequently prescribed for pain management in the United States and 
worldwide(Docherty, Jones, and Wallace 2011). In the United States, approximately 100 
million people suffer from chronic pain(Stayner and Copenhaver 2012), and 5% of the 
U.S. population use opioids drug prescription(Boudreau et al. 2009). However, serious 
side effects such as addiction, immunosuppression and gastrointestinal symptoms limit 
their use. These GI symptoms include constipation, bloating, nausea, vomiting. Previous 
studies in our laboratory and other research groups have demonstrated that morphine 
disrupts intestinal barrier function and induces bacterial translocation in mice(Meng et al. 
2013). Use of opioids are associated with an increased risk of C. difficile infection in 
human patients(Mora et al. 2012). Morphine treatment can activate the virulent factors of 
Pseudomona and induce gut derived sepsis(Babrowski et al. 2012). Our laboratory’s 
study has confirmed that morphine induced sepsis is mediated through modulation of 
miR-146a(Banerjee et al. 2013). Our study revealed that opioid exacerbation of gram-
positive sepsis is rescued by IL-17A neutralization(Meng et al. 2015). It has been shown 
that the disruption of barrier function and increased growth of pathogenic bacteria are 
major factors that disrupts gut homeostasis(Marchiando, Graham, and Turner 2010; Estes 
et al. 2010; Sartor 2008; Kamada and Núñez 2013).  
Gut homeostasis refers to a symbiotic relationship between the commensal 
microbiota and the host(Chassaing et al. 2012; Faust et al. 2012). It is maintained through 
interactions between gut microbiota and the host. An estimated 1014 bacteria colonize 
within the human intestinal tract(Nieuwdorp et al. 2014) which is 10 times greater than 
amount of human cells. There are more than 10 thousand unique species in gut 
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microbiota, and their genetic load are 150 times greater than human genome(Honda and 
Littman 2012). The total mass of human gut microbiota is about 2 to 6 pounds(Forsythe 
et al. 2010). Changes in the composition of the microbiota can contribute to diseases, 
such as obesity, diabetes, autoimmune diseases, inflammatory bowel disease (IBD), and 
infectious diseases(Zhao 2013; Wen et al. 2008; Severance, Yolken, and Eaton 2014; 
Bassett et al. 2015). However, very little is known how exogenous (diet, drugs, and 
infectious microorganism) and endogenous (the immune system, genetic background) 
factors modulate the formation and homeostasis of gut microbiota. Humans and animals 
are born into the world in a state free from microbial contamination, particularly within 
their gastrointestinal tract(van de Pavert et al. 2014). During birth and thereafter, they are 
exposed to microbes. Gut microbiota make important contributions to the health and well 
being of animals and humans, for example, nutrition metabolism, immune development, 
and CNS development(Ochoa-Repáraz and Kasper 2014; Cullender et al. 2013). 
Particularly, babies acquire microbes from their mothers. Infants born by C-section have 
a different microbiota composition as compared with vaginally delivered newborn 
infants(Dominguez-Bello et al. 2010). Vaginally delivered infants come in contact with 
the maternal vaginal and faecal microbiota which results in the gut colonization by 
microbes from mother’s birth canal. In infants born by C-section, the establishment of gut 
microbiota is delayed. Breastfed infants exhibit significant differences in gut microbiota 
as compared with formula fed(Ding and Schloss 2014). Breast milk has been shown to be 
an excellent and continuous source of bacteria. 
Gut microbiota play an important role in maintaining gut homeostasis. The 
symbiotic relationship between commensal microbiota and the host achieve a balanced, 
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mutually beneficial state. Alteration in gut microbiome and metabolome has been shown 
to contribute to dysregulated immune response, bowel dysfunction and gut barrier 
disruption(Vangay et al. 2015; Diehl et al. 2013). However, the effect of opioids on gut 
microbiota has not been investigated. In this study, we use a mouse model of morphine 
treatment. In the experiment, pellets were implanted subcutaneously to mice. Fecal 
samples were collected at day 0, day 1, day 2 and day 3 post treatment. Then, fecal DNA 
were extracted, 16s-rRNA genes were amplified by using V4 primers, then proceeded by 
Illumina MiSeq sequencing. The gut microbiome profile exhibits a distinct signature 
following morphine treatment when compared to placebo treatment.  
Alpha diversity refers to diversity of species within a habitat unit(The Human 
Microbiome Project Consortium. 2012; Walter and Ley 2011). It answers questions: 
What is there? How much is there? Morphine treatment results in decreased alpha 
diversity when compared to controls. Richness of microbial diversity is an indicator of 
microbial homeostasis and less microbial diversity is associated with microbial dysbiosis 
(Antharam et al. 2013). Morphine treatment is associated with a significant decrease in 
gut microbial alpha diversity, indicating microbial dysbiosis and higher risk for dysbiosis 
and infectious diseases. 
Beta diversity refers to diversity between habitat units(Schloss 2010). It answers 
question: How similar or different are samples? Each dot represents a sample, the 
position and distance between dots reflect similarity of microbiome profile. The closer 
clustering means higher similarity and less difference. Our study shows that morphine 
treatment results in a significant shift in fecal microbiome when compared to placebo 
treatment. A cladogram of phylogenetic tree shows distinct clustering by comparing 
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morphine treatment and placebo. Furthermore, a dendrogram of gut microbiome reveals 
that housing animals in separate boxes does not result in individual differences, when 
compared with effects of treatments. 
Then, we use an opiate receptor antagonist, naltrexone, to determine if it can 
inhibit effect of morphine on gut microbiome. Our study shows that prior to treatment all 
fecal samples have similar gut microbiome. On day 1 post treatment, morphine treated 
groups were distinct from morphine, naltrexone, naltrexone plus morphine treatment.  In 
this time course study, we found naltrexone antagonizes morphine-induced alteration of 
gut microbiome. Interestingly, animals treated with naltrexone alone clustered distinctly 
from the placebo group at day 3 post treatment suggesting that endogenous opioid may 
set a basal tone on the host microbial profile. 
To further determine if morphine treatment results in functional consequence 
following gut microbiome alteration, predicted metagenomic functional analysis was 
performed using a BugBase software package. Our results show that morphine treatment 
resulted in a significant increase in pathogenic function of gut microbes. Furthermore, 
there is a decrease in stress tolerance of gut microbiome indicating decreased resilience 
against perturbation to gut homeostasis. These results implicate that morphine-treated gut 
microbiota might be less likely to outcompete outgrowth of pathogenic bacteria and 
eliminate pathogens colonization in the gut. Less stress tolerance of the gut microbiota 
community means that the homeostasis is more “fragile” or susceptible.  
By using phylogenetic analysis, we found morphine treatment results in a 
significant increase of potential pathogenic bacteria. The analysis of OTUs on genus level 
shows that relative abundance of potential pathogenic bacteria (genus level) increased 
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significantly at day 3 post morphine treatment compared to placebo treatment. Multiple-
test with the given threshold (FDR=0.05) shows relative abundance of pathogenic 
bacteria of genus level increase significantly at day 3 post-treatment with morphine 
treatment compared to placebo treatment. Increased representative potentially pathogenic 
bacteria include Flavobacterium, Enterococcus, Fusobacterium, Sutterella, Clostridium, 
etc. 
In order to confirm the pathogenic strains that constitutes distinctness of gut 
microbiome alteration, we detected expression profiling of selected species specific 
16SrRNA genes in gut microbiota by using quantitative real-time PCR. The result shows 
that expansion of Enterocuccus faecalis is associated with morphine induced alteration of 
gut microbiome. E. faecalis 16S-rRNA gene amplification was 100 times greater in 
morphine modulated gut microbiome than placebo treated gut microbiome. The effect of 
morphine on E. faecalis expansion was observed as early as day 1 in morphine treated 
animals and sustained in all days tested post treatment. The effect of morphine on E. 
faecalis abundance in the gut microbiome was antagonized by naltrexone treatment. This 
results suggest that expansion of E. faecalis can potentially act as a biomarker of gut 
dysbiosis following morphine treatment. 
High risk of bacterial infection in hospitalized patients is a significant concern 
especially in those patients that are on opioids for pain management. C. rodentium is a 
natural mouse pathogen that models intestinal infection by E. coli (Enterohaemorrhagic 
Escherichia coli, EHEC) in human and animal hosts(Yi and Goldberg 2009). While 
establishing colonization, C. rodentium delivers a variety of virulence factors, such as 
translocated intimin receptor (Tir), into epithelial cells by means of the type III secretion 
109 
 
system in order to facilitate their adherence and invasion(Kamada et al. 2012). EspFU 
directly binds and activates N-WASP, leading to actin polymerization events. The 
expression of most virulence genes in C. rodentium is controlled by a regulator, Ler 
protein, a member of the histone-like nucleoid structuring (H-NS) protein family. Thus, 
Ler is a virulence factor that regulates C. rodentium virulence. It has been known that 
wild type mice are able to clear C. rodentium infection(Kamada et al. 2012). We next 
asked the question whether morphine can increase C. rodentium growth in intestine 
contents and modulate gut microbiome in the context of C. rodentium infection.  The 
results show that morphine increases C. rodentium load in fecal matter at day 5 post 
infection. Furthermore, to determine C. rodentium bacterial adherence to intestines, we 
conducted Fluorescent in situ hybridization (FISH) on tissue sections by using specific 
profess to detect C. rodentium. The FISH results reveal that morphine treatment increases 
C. rodentium adherence to small intestines and colon, when compared to placebo 
treatment. 
Pathogen colonization in the intestine has been shown to be controlled by 
bacterial virulence and through competition with gut commensal microbiota. To 
investigate if morphine treatment increases C. rodentium virulence, we determined 
virulence factors, ler and tir, mRNA levels by qPCR in fecal pellets of mice infected with 
C. rodentium at day 5 post infection. Expression was normalized to that of the 16S rRNA 
genes. Expression of virulence factors, Ler and Tir, were significantly increased in the 
morphine treatment group when compared to placebo. Same effects were seen in fecal 
samples of small intestines, cecum and colon. 
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At day 5 post C. rodentium infection, when compared to placebo treatment, mice 
receiving morphine revealed an increased number of colonies growing on the antibiotic 
selective LB agar plates, indicating systemic dissemination of C. rodentium into 
mesenteric lymph nodes, spleen, liver and blood circulation.  
Beta diversity analysis results revealed morphine treatment shifts gut microbiome 
in the context of C. rodentium infection, indicating that the relative bacterial abundance 
and composition in gut were changed. The Principle coordinate plot reveals that primary 
clustering is by C. rodentium infection. Furthermore, UniFrac measure shows that 
morphine treatment induces distinct gut microbiome in the context of C. rodentium 
infection. 
To begin to understand early events that occur in morphine-treated mice that can 
precipitate increased C. rodentium infection, we evaluated the extent of epithelial damage 
at day 5 post infection. Histologic evaluation revealed that morphine treatment disrupts 
morphological structure of mucosal surface of intestines. Histological evaluation of the 
tight junction protein ZO-1 on sections of jelly-rolled small intestines reveals that 
morphine treatment decreases tight-junction organization between intestinal epithelial 
cells(Meng et al. 2013; H. Wang et al. 2008). However, C. rodentium infection alone 
does not result in histological damages in intestinal mucosal epithelial integrity and 
barrier function at day 5 post infection.  
In the early stage of infection pathogenic bacteria require virulence factor-
mediated adhesion(Minsoo Kim et al. 2009; Hew, Korakli, and Vogel 2007). In the late 
phase, virulence factor is downregulated and healthy intestinal microbiota would 
outcompete the pathogen. Our study shows that morphine treatment induces microbial 
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dysbiosis, gut barrier dysfunction, and dysregulated immune response. In a mouse model 
of C. rodentium infection, morphine treatment results in 1) increase of virulence factors 
expression, 2) increase of pathogen outgrowth and colonization in gut, 3) Alteration of 
gut microbiome, 4) damaged integrity of gut epithelial barrier function, and 5) the 
promotion of C. rodentium systemic dissemination.  
Microbial dysbiosis leading to a disruption of host-microbes homeostasis is not 
only alteration of microbial composition, but more importantly disruption of functional 
consequence of the microbiota. Previous studies have been well demonstrated that gut 
metabolites play an important link between gut microbes and host biological 
functions(Nicholson et al. 2012). For example, bile acids can mediate resistance to C. 
difficile infection. Bacterial metabolites regulate GI barrier function via Xenobiotic 
Sensor PXR and TLR4(Venkatesh et al. 2014; Hagey and Krasowski 2013). However, it 
is still unknown how morphine treatment can modulate composition and abundance of 
gut metabolites. Gut bacteria play an important role in bile acid and morphine 
metabolism in gut. Primary bile acids and M3G (Morphine-3-glucuronide) are produced 
in live and excreted into intestine through bile duct(Klepstad et al. 2003; Oliveira et al. 
2014). In gut, deconjugating bacteria facilitate their metabolism(Van Crugten et al. 
1991). It is unknown whether morphine-induced microbial dysbiosis can modulate bile 
acids and morphine metabolism in gut. Morphine is conjugated to morphine-3-
glucuronide (M3G) in liver and excreted to gut via biliary tract. Intestinal deconjugating 
bacteria transform M3G to morphine, which is reabsorbed back to systemic circulation. 
To determine the effect of morphine treatment on gut metabolome, the same 
samples previously used for gut microbiome analysis, are used for metabolomic analysis. 
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LC-MS based metabolomics analysis are able to determine composition and abundance 
of gut metabolites(Shi, Yao, and Chen 2012; Yao et al. 2013). In this study, morphine 
treatment induces distinct gut metabolomics profile when compared to placebo at day 3 
post treatment. To identify metabolites contributing to distinct metabolome following 
morphine or placebo treatments, we performed a loading plot of principal components 
analysis model in which each dot represents a single molecular metabolite. It has been 
shown through the loading plot that the abundance of certain metabolites are increased by 
morphine treatment while certain metabolites are decreased by morphine treatment. 
In a longitudinal study, fecal matters were taken from mice at prior to and day 1, 
day 2, day 3 post morphine or placebo treatment. Metabolic profile following morphine 
treatment was determined by analyzing molecular metabolites extracted from these fecal 
matters. Our results show that morphine treatment resulted in a gradual and differential 
shift in metabolites in a time dependent manner. Bile acids decreased gradually, while 
phosphatidylethanolamines (PEs) and saturated fatty acids increased as a consequence of 
morphine treatment. 
We used an opioid receptor antagonist, naltrexone, to determine whether it can 
reverse effect of morphine on gut metabolomics profile. The result shows that naltrexone 
can alleviate morphine induced gut metabolomics shift and reverse the effect of morphine 
on bile acid metabolism. This figure shows that, the abundance of secondary bile acid, 
deoxycholic acid significantly decreased following morphine treatment and morphine 
induced decrease was antagonized by naltrexone. The abundance of phospholipid, PE, 
which is a major component of cell membrane, was increased by morphine treatment, 
indicating increased cell injury, but morphine induced increased was inhibited by 
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naltrexone treatment. This result indicates that deoxycholic acid (DCA) levels and 
phosphatidylethanolamines (PE) can be used as biomarkers to indicate morphine-
modulation of gut metabolome. 
Morphine is conjugated to morphine-3-glucuronide (M3G) in liver and excreted 
to gut via biliary tract. Intestinal de-conjugating bacteria transform M3G to morphine, 
which is reabsorbed back to systemic circulation. We found that the ratio of M3G/MS 
serum concentration increases in a time course study. The slow-released morphine from 
pallet implantation and morphine from reabsorption can make a stable serum 
concentration of morphine. The decrease of morphine serum concentration indicates 
disruption of morphine biotransformation and reabsorption in gut. The ratio of M3G/MS 
also increases in feces between day 1 and day 2 post morphine treatment, indicating 
decreased M3G deconjugation in the gut.  
To summarize effects of morphine treatment on gut metabolome, morphine 
treatment when compared to placebo, 1) results in dramatic changes in the fecal 
metabolome; 2) differentially and gradually alters fatty acids and bile acids, 3) increases 
PE levels indicating significant cell injury. It is worthy to note that morphine induced 
dysbiosis disrupts morphine metabolism and its enterohepatic recirculation. 
My study reveals opioids-induced distinct alteration of gut microbiome and 
metabolome, may contribute to opioids-induced pathogenesis and morphine 
pharmacokinetics. This is the first study to demonstrate that morphine promotes pathogen 
dissemination in the context of intestinal C. rodentium infection, indicating morphine 
modulates virulence factor-mediated adhesion of pathogenic bacteria and induces 
disruption of mucosal host defense during C. rodentium intestinal infection in mice. 
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Potential Problems and Future Directions 
Gut microbiome analysis 
Rapid progress in next generation sequencing has provided a new tool to 
investigate the gut microbiome and helped us complete mission that was impossible to do 
so. However, technology limitation still remains as major obstacles.  
Firstly, current 16S rRNA genes analysis can only provide limited approaches. 
There are conserved regions and variable regions on 16S rRNA genes. We identify and 
classify organisms by gene sequence variations. Carl Woese and George E. Fox were the 
first to investigate bacterial phylogeny by using 16S rRNA genes(Woese and Fox 1977). 
Because no primer pair is completely universal, primer specificity leads to an acceptable 
bias (Tremblay et al. 2015). It is possible that certain amount of organisms can’t be 
identified when using primers against V4 regions of 16S rRNA sequences. It has been 
shown, MiSeq V4 exhibits the highest similarity to reach the expected taxonomic 
distribution and shotgun libraries, and results in highest quality, by comparing primer 
(V4, V7-8, and V6-V8) and platform (454 pyrosequencing and Illumina MiSeq) effects 
(Tremblay et al. 2015). A variety of studies comparing amplicons from different 
hypervariable regions all revealed that V4 amplicons exhibit the greatest similarity to 
shotgun sequencing bacterial community profiles(Kumar et al. 2011; Ward et al. 2012; 
Minseok Kim, Morrison, and Yu 2011; He et al. 2015). Thus, in this study we use 
primers for V4 regions to amplify 16S rRNA genes. 
Secondly, reference database per se has been limited. Operational taxonomic unit 
(OTU) is an operational definition of a species or group of species. It's a unique number 
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for each group of species and differentiated by the sequence similarity. OTU ID is 
assigned to the center sequence of the nested cluster, and all the other sequences share the 
same OTU ID share the same OTU ID at the same level. Normally, we use 97% of 
similarity level. The taxonomic database we are currently using is GreenGenes (v13_5). 
It covers Archaea and Bacteria including 1,262,986 sequences. When we use 99% cut off 
value, we limit the reference base to 203,452 OTUs, while when we use 97% cut off 
value, we limit the reference base to 99,322 OTUs. OTUs are not identically equal to 
bacterial strains; chimeric and miss-annotated OTU picking may contribute to a higher 
errors; taxonomy updates lags years behind, indicating many unclassified. Furthermore, 
the GreenGene (v13_5) overlooks intestinal fungi which can only be identified by 18S 
rRNA genes. 
Thirdly, OTU picking methods is limited. In this study, we use closed-reference 
OTU picking. Any reads that don’t hit a reference sequence are discarded. We are also 
able to use de novo clustering, or open-reference OTU picking. In de novo clustering 
method, reads are clustered based on similarity to one another. Open-reference OTU 
picking considers any reads which don’t hit a reference sequence are clustered de novo.  
Fourthly, 16S rRNA sequences analysis can’t tell you information on metabolic 
profiles. Microbiome information obtained from 16S rRNA sequencing tells us what taxa 
are in the habitat unit (who’s there), while information on biological functions can only 
be indirectly obtained from 16S rRNA sequences. We can predict function based on 
taxonomy using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction 
of Unobserved States). In this study, we use BugBase packages, which relies on PICRUSt 
and KEGG database to predict biological functions based on 16S rRNA genes 
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sequencing(Langille et al. 2013). Alternatively, whole genome shotgun sequencing and 
RNASeq may provide better approaches to investigate biological functions. As 
technology progresses it may help decrease cost in genes sequencing, thus provide access 
to a better understanding of gut microbiome and their biological functions. 
Fifthly, it is not clear how the results of our study about discovery of morphine-
induced gut microbiome and metabolome alteration can be correlated with previously 
well established study on effects of morphine on host phenotype, behavior, immune 
response. It would be meaningful in terms of diagnostics or therapeutics to identify which 
determinants account for morphine-induced microbiome alteration and how the host 
genotypes, diet, metabolic and immune factors, as well as pathologic outcome, can affect 
gut microbiome. A genetic method, multitaxon Insertion Sequencing (INSeq) has been 
developed to determine precision microbiota manipulation and identify determinants that 
affect microbiota(Goodman, Wu, and Gordon 2011). By using INSeq technology, Wu, et 
al generated unique mutants of bacteria with a single insertion of isogenic transposon to 
each strain to identify genetic and metabolic factors that account for change of gut 
microbiome through analyzing relationship between mutation and bacterial abundance 
differences(M. Wu et al. 2015).  This INSeq method can be applied in our future study to 
identify major determinants that involve in the morphine-induced microbial dysbiosis. 
 
Host-microbes interaction and diseases 
Alteration of gut microbiome is associated with many diseases, such as obesity, 
diabetes, autoimmune diseases, inflammatory bowel disease, colon cancer, and higher 
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risk of infections. Our study suggests morphine-induced gut microbiome alteration is 
associated with higher susceptibility to bacterial infections. The distinctness of morphine-
modulated gut microbiome and metabolome provide potential diagnostic strategies. 
However, it is still unclear how clinical intervention alleviates morphine-induced adverse 
effects. After understanding mechanism that gut commensal microbiota outcompete 
pathogens we may take good advantage of clinical intervention by using commensal 
species to limit pathogen colonization and invasion. Fecal microbiota transplantation has 
shown to be promising therapeutic intervention clinically in curing recurrent C. difficile 
infection (CDI)(Weingarden et al. 2014; Cammarota, Ianiro, and Gasbarrini 2014). Also, 
the nutrition resource plays an important role in modulating the gut microbiota. Literature 
shows that commensals and pathogenic bacteria may grow on structurally similar 
nutrition(Kamada et al. 2012). Thus, nutrition competition plays a crucial role in clearing 
pathogenic bacteria from the gut. It would be a potential therapeutic strategy for 
prevention or intervention of intestinal infection in terms of modulation of gut microbiota 
during pain management using morphine. 
In this longitudinal study, morphine treatment induces microbial dysbiosis and 
functional consequences following microbial dysbiosis exhibit a time-course dependent 
fashion. However, it is still unknown how long the microbial dysbiosis and its effect may 
remain. The morphine serum levels remained elevated at least within 144 hours following 
pellet implantation(Patrick et al. 1975).  It would be worthy to investigate effect of 
morphine on gut homeostasis in the longer term study and under different drug 
administration methods, such as i.p. injection or intravenous infusion pump. It is 
interesting to reveal whether and if so, how long it takes to reach the recovery of gut 
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homeostasis or remain vicious loop of microbial dysbiosis. To be noted, morphine 
withdrawal-induced immunosuppression and high risk of bacterial infection has been 
well investigated(Das et al. 2011; Feng et al. 2005; Sabita Roy et al. 2011), however, 
effects of morphine withdrawal on gut microbiome and their relationship with 
pathological outcome is still unknown. 
It has been shown that morphine-induced microbial dysbiosis exhibits a signature 
of distinctness. However, it is unclear the direct relationship between gut microbiome 
disruption and pathological outcomes. Gnotobiotic mouse model has been widely used in 
determine the direct relationship in host-microbes interaction(Reyes et al. 2013). Some 
concerns, such as unmatured immune system and abnormal physiological phenotypes, 
limit their use(Chung et al. 2012; Kau et al. 2011; Erny et al. 2015). Our laboratory’s 
study of fecal transplantation in SPF mice has shown that transplantation of morphine 
modulated fecal matters to non-treated mouse can lead to pathological consequence 
similar to that of morphine treated mice, indicating direct effect of microbial dysbiosis on 
pathological consequence in the host (unpublished data). However, it is not known which 
bacteria can determine the pathological outcomes, such as immune response, 
physiological development or behavior changes. Through precision antibiotic 
manipulation of gut microbiome, the mechanism under which gut bacteria account for 
morphine-induced pathological consequence can be better determined in future study.  
A common concern of mouse model is its limitation, especially on immune 
systems and gut microbiome composition, when compared to human subjects. 
Humanized NSG™ (hu-NSG™) mouse models is a mouse model with humanized 
immune systems. By generating humanized gut microbiome within gastrointestinal tract 
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of humanized NSG mouse models may provide a powerful tool to expand the impact of 
study on mice. 
Better understanding mechanism of vulnerability to infection in patients under 
pain management and drug abusers can help develop therapeutic strategy following our 
study. After elucidating the mechanism by which morphine modulates host immune 
system and gut microbiota, we may conduct intervention of cytokines, such as IL-17A, or 
antibodies, such as IgA, antimicrobial peptides (AMPs) to reverse side effects of 
morphine.  
Our previous study showed that IL17A neutralization can rescue opioid 
exacerbation of gram positive sepsis induced by cecal ligation and puncture (CLP)(Meng 
et al. 2015). Meng et al, demonstrated that IL17A neutralization act as anti-inflammatory 
effects, which improves the survival rate and sustains inflammation in CLP mice treated 
with morphine. Furthermore, high levels of IL-17A compromise gut epithelial barrier 
function and increase gut permeability in morphine treated CLP animals. Thus, IL-17A 
seems to play a negative role. However, in present study, we found morphine treatment 
suppresses C. rodentium-induced IL17A immune response, inhibits C. rodentium 
clearance and promotes systemic dissemination. It has been well demonstrated that IL-17 
and IL-22 enhance innate barrier defenses against C. rodentium, and induce antimicrobial 
peptide production and neutrophil recruitment, indicating a protective role(Geddes et al. 
2011; Rubino, Geddes, and Girardin 2012; Z. Wang et al. 2014). The role that IL-17A 
plays in these two scenarios brings up a paradox about inflammation and pathogenesis. 
Pro-inflammatory response to pathogen infection improves bacterial clearance and is part 
of self-protection mechanism of host defense. However, inflammation may also lead to 
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overreaction or dysregulated immune response that disrupts homeostasis and damage host 
physiological function. Similarly, gut commensal microbiota, which is characterized by 
adaptability and resilience against perturbation, play an important role in maintain gut 
homeostasis and outcompete invading pathogens. However, highly virulent pathogens are 
capable of colonization in gut, adherence to mucosal epithelium, and translocation to 
systemic circulation. During this process, invading pathogens results in microbial 
dysbiosis, which therefore leads to dysregulated immune response and intestinal barrier 
dysfunction. Thus, the thought of pathogenesis seems beyond infection and disease, but is 
focused on host-microbes interaction. Here the question is not about whether infection 
induces disease. The question is whether host-microbes interaction damages host. In this 
way, we may better understand pathogenesis and find an appropriate way to cure 
diseases.  
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